BLINK Study Protocol (COVSBCC0549) 
Version  6.0 ClinicalTrials.gov Cover Page
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template This document is electronically controlledClinical Investigation Plan 
Clinical Investigation Plan/Study Title Multicenter, prospective study comparing 
PillCam ®Crohn’s capsule endoscopy (CE) to 
ileocolonoscopy (IC) plus MRE for detection of 
active Crohn’s Disease (CD) in the small bowel 
and colon in subjects with known CD and mucosal 
disease (the BLINK study)
Clinical Investigation Plan Identifier COVSBCC0549
Study Product Name PillCam ®Crohn’s capsule endoscopy system
NCT [STUDY_ID_REMOVED]
Document Version / Date 6.0 / 16November2018

BLINK Clinical Investigation Plan 
Version 6.0 Page 1 of 82  
Medtronic Confidential  
This document is electronically  controlled 056-F275, v3.0 Clinic al Investigation Plan TemplateClinical Investigation Plan  
Clinical Investigation Plan/Study Title Multicenter, prospective study comparing 
PillCam ® Crohn’s capsule endoscopy (CE) to 
ileocolonoscopy  (IC) plus MRE for detection of 
active Crohn’s Disease (CD) in the small bowel 
and colon in subjects wi th known CD and mucosal 
disease (the BLINK study)  
Clinical Investigation Plan Identifier COVSBCC0549  
Study Product Name PillCam ® Crohn’s capsule endoscopy system  
Sponsor/Local Sponsor United States:  
Medtronic MITG Early Technologies GI Solutions 
A Medtronic company (“Medtronic”)  
555 Long Wharf Dr,  
New Haven, CT 06511  
Phone: +(1)(203)562 -1620 
Europe:  
Medtronic MITG Early Technolog ies GI Solutions  
A Medtronic company (“Medtronic”)  
Covidien Services Europe, Ltd.,  
Block G, First Floor  
Cherrywood Business & Technology Park  
Loughlinstown, Dublin 18, Ireland  
Phone: +(353) -(1)-4393000 
Israel:  
Medtronic MITG Early Technologies GI Solutions  
(Given Imaging Ltd.)  
A Medtronic company (“Medtronic”)  
2 Hacarmel St. New Industrial Park  
POB 258, 20692 Yoqneam, Israel  
Phone: +(972) -(4)-909-7700 
Document Version 6.0 / 16November2018  

BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 2 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Lead Principal Investigator(s) David H. Bruining, MD  
Division of Gastroenterology and Hepatology,   
Mayo Clinic College of Medicine,                            
200 1st St SW,                                        
Rochester, MN 55905,                                     
USA 
Confidentiality Statement 
The information contained in this document is  confidential and the proprietary property of 
Medtronic. Any distribution, copying, or disclosure without the prior written authorization of 
Medtronic is strictly prohibited. Persons to whom the information is disclosed must know that it is  
confidential and that it may not be further disclosed by them. 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 3 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  1. Investigator Statement 
Study product Name PillCam ® Crohn’s capsule endoscopy system 
Sponsor  United States:  
Medtronic MITG Early Technologies GI Solutions  
A Medtronic company (“Medtronic”)  
555 Long Wharf Dr,  
New Haven, CT 06511  
Phone: +(1) -(203)-562-1620 
Europe:  
Medtronic MITG Early Technologies GI Solutions  
A Medtronic company (“Medtronic”)  
Covidien Services Europe, Ltd.,  
Block G, First Floor  
Cherrywood Business & Technology Park  
Loughlinstown, Dublin 18, Ireland  
Phone: +(353) -(1)-439300 
Israel:  
Medtronic MITG Early Technologies GI Solutions  
(Given Imaging Ltd.)  
A Medtronic company (“Medtron ic”) 
2 Hacarmel St. New Industrial Park  
POB 258, 20692 Yoqneam, Israel  
Phone: +(972)-(4)-909-7700 
Clinical Investigation Plan Identifier COVSBCC0549 
Version Number/Date  Version 6.0 - 16November2018 
I have read the protocol, including all appendices, and I agree that it contains all necessary details for me 
and my staff to conduct this study as  described. I will conduct this study as outlined herein and will make a 
reasonable effort to complete the study within the time designated.  
I agree to comply with United Stated Food and Drug Administration abbreviated requirements as defined in 
21CFR812.2(b)(US) or local laws and regulations as required for post -market clinical trials (Outside of the 
US). I agree to ensure that  the confidential inform ation contained in this document will not be used for any 
purpose other than the evaluation an d conduct of the clinical investigat ion without the prior written consent 
of Medtronic.  
I will provide all study personnel under my supervision copies of the prot ocol and access to all information 
provided by Medtronic. I will discuss this material with them to ensure that they are fully informed about the 
products and the study.  
Investigator’s Signature:  
Investigator’s Name:  
Institution:  
Date:   
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 4 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
   
Table of Contents  
 
1. Investigator Statement ...................................................................................................... 3  
Table of Contents ............................................................................................................. ......... 4  
2. Glossary .............................................................................................................................. 9 
3. Synopsis ...................................................................................................................... ..... 12  
4. Introduction .................................................................................................................. ... 15  
4.1. Background .................................................................................................................... ....... 15 
4.2. Purpose ............................................................................................................................... .. 16 
5. Objectives and Endpoints ................................................................................................. 17  
5.1. Objectives .................................................................................................................... ......... 17 
5.1.1. Primary Objective(s) ................................................................................................... ........... 17 
5.1.2. Secondary Objective(s).................................................................................................. ........ 17 
5.2    Endpoints ............................................................................................................................. 17 
5.2.1 Primary Endpoint ........................................................................................................ ............... 17 
5.2.2 Secondary Endpoints ..................................................................................................... ............ 17 
5.2.3 Safety Endpoints ........................................................................................................ ................ 18 
6. Study Design .................................................................................................................. .. 18  
6.1. Duration ...................................................................................................................... .......... 18 
6.2. Rationale ..................................................................................................................... .......... 19 
7. Product Description.......................................................................................................... 1 9 
7.1. General ....................................................................................................................... .......... 19 
7.2. Dosage Form and Route of  Administration ............................................................................... 20 
7.3. Manufacturer .................................................................................................................. ....... 20 
7.4. Packaging .............................................................................................................................. 20 
7.5. Intended Population ........................................................................................................... .... 20 
7.6. Equipment ..................................................................................................................... ........ 21 
7.6.1 PillCam® Crohn’s Capsule ................................................................................................ ...... 21 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 5 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  7.6.2 PillCam Recorder (DR3) .................................................................................................. ....... 21 
7.6.3 PillCam Workstation ..................................................................................................... ......... 21 
7.7. Product Use ................................................................................................................... ........ 22 
7.8. Product Training Requirements ............................................................................................... 22 
7.9. Product Receipt and Tracking ................................................................................................. 22 
7.10.  Product Storage ...............................................................................................................  22 
7.11.  Product Return ................................................................................................................. 23 
7.12.  Product Accountability ...................................................................................................... 23 
8. Selection of Subjects ........................................................................................................ 24  
8.1. Study Population .................................................................................................................... 24 
8.2. Subject Enrollment ............................................................................................................ ..... 24 
8.3. Inclusion Criteria ............................................................................................................ ........ 24 
8.4. Exclusion Criteria ............................................................................................................ ....... 24 
9. Study Procedures ............................................................................................................. 25 
9.1. Schedule of Events ................................................................................................................. 25 
9.2. Subject Consent ..................................................................................................................... 26 
9.3. Subject Screening ............................................................................................................. ..... 28 
9.4. Baseline ...................................................................................................................... .......... 29 
9.5. Medication Compliance ......................................................................................................... .. 30 
9.6. Magnetic Resonance Enterography .......................................................................................... 30 
9.7. PillCam Patency Study ......................................................................................................... ... 30 
9.8. Capsule Endoscopy Procedure ................................................................................................ 30 
9.9. Ileocolonoscopy ............................................................................................................... ...... 31 
9.10.  Central Reader Image/Video Reading ................................................................................ 31 
9.10.1 Imaging Scores fo r Central Reading ................................................................................... 3 2 
9.11.  Assessment of Efficacy ..................................................................................................... 33 
9.12.  Assessment of Safety ....................................................................................................... 33 
9.13.  Recording Data ................................................................................................................  34 
9.14.  Deviation Handling ........................................................................................................... 34 
9.15.  Subject Withdrawal or Discontinuation ............................................................................... 35 
10. Risks and Benefits ............................................................................................................  36 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 6 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  10.1.  Potential Risks .................................................................................................................. 36 
10.1.1 PillCam® Crohn’s Capsule ............................................................................................... ... 36 
10.1.2 MRE .................................................................................................................... ................ 36 
10.1.3 Ileocolonoscopy ........................................................................................................ ......... 37 
10.2.  Potential Benefits ............................................................................................................ . 37 
10.3.  Risk-Benefit Rationale ....................................................................................................... 38 
11. Adverse Events and Device Deficiencies .......................................................................... 38  
11.1.  Definitions/Classifications .................................................................................................. 38 
11.1.1 Adverse Event (AE) ..................................................................................................... ....... 39 
11.1.2 Serious Advers e Event (SAE) ............................................................................................ .. 39 
11.1.3 Customer Complaint ..................................................................................................... ..... 40 
11.1.4 Device Deficiency ...................................................................................................... ......... 40 
11.1.5 Adverse Event Severity Classification ................................................................................ 4 0 
11.1.6 Adverse Event Relationsh ip Classification ......................................................................... 40 
11.1.7 Adverse Event Outcome Classification .............................................................................. 42 
11.2.  Recording of Adverse Events ............................................................................................. 43 
11.3.  Reporting of Adverse Events ............................................................................................. 43 
11.4.  Notification to Authorities.................................................................................................. 44 
11.5.  Device Deficien cies ...........................................................................................................  44 
12. Data Review Committees ................................................................................................. 44  
12.1 Medical Advisor ...................................................................................................................... 45 
12.2 Steering Co mmittee ....................................................................................................... ........ 45 
13. Statistical Design and Methods ........................................................................................ 45  
13.1  Sample Size Determination .....................................................................................................  45 
13.2  Effectiveness Analyses ............................................................................................................ 45 
13.3  Safety Analysis................................................................................................................ ....... 45 
13.4  Analysis Populations .......................................................................................................... ..... 45 
13.5  Interim Analy ses .............................................................................................................. ...... 46 
13.6  Handling of Missing Data ...................................................................................................... .. 46 
14. Ethics ........................................................................................................................ ........ 46  
14.1.  Statement(s) of Compliance .............................................................................................. 46 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 7 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  15. Study Administration ....................................................................................................... 47  
15.1.  Monitoring .................................................................................................................... ... 47 
15.2.  Data Management ............................................................................................................ 48 
15.2.1 Data Collection ........................................................................................................ .......... 48 
15.2.2 Data Access ............................................................................................................ ............ 48 
15.2.3 Electronic Case Report  Form Guidelines ........................................................................... 48 
15.2.4 Data Queries ........................................................................................................... ........... 48 
15.2.5 Audits and Inspections ................................................................................................. ..... 49 
15.2.6 Close Out .............................................................................................................. ............. 49 
15.3.  Direct Access to Source Data/Documents ........................................................................... 49 
15.4.  Confidentiality ............................................................................................................... ... 49 
15.5.  Liability ..................................................................................................................... ....... 50 
15.6.  CIP Amendments ............................................................................................................. 50 
15.7.  Record Retention ............................................................................................................. 50 
15.8.  Publication and Use of Information .................................................................................... 51 
15.9.  Suspension or Early Termination ....................................................................................... 51 
16. References .................................................................................................................... ... 52  
17. Appendices .................................................................................................................... ... 55  
17.1 Appendix A – Montreal Classification ..................................................................................... .. 56 
17.2 Appendix B - Study Schedule for Clin ical Laboratory and Pregnancy Tests ................................. 57 
17.3 Appendix C - MRE Procedure Instructions ................................................................................ 59 
17.3.1 Appendix C1 - MRE Su bject Instructions ................................................................................. . 60 
17.4 Appendix D – PillCam ® Patency Study .................................................................................... 61 
17.5 Appendix E – CE and IC Procedure Instructions ....................................................................... 62 
17.5.1 Appendix E1 – CE and IC Bowe l Preparation Instructions ................................................. 63 
17.5.2 Appendix E2 – CE and IC Su bject Instructions  Form .......................................................... 65 
17.5.3 Appendix E3 – CE Procedure Instructions ......................................................................... 66 
17.5.4 Appendix E4 – CE and IC  Bowel Cleansing Scale ...................................................................... 68 
17.7  Appendix F – Accuracy for Active Crohn’s Dise ase in Overall and Designated Bowel Segments .... 69 
17.8  Appendix G – Scores for Capsule endoscopy, Ileocolonoscopy, and MRE ................................... 70 
17.8.1 Appendix G1 – Lewis Score .............................................................................................. .. 71 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 8 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.8.2 Appendix G2 – Simple Endoscopic Score fo r Crohn’s Disease Index (SES-CD) Score ........ 72 
17.8.3 Appendix G3 - Magnetic Resonance Index of Activity (MaRIA) Score ............................... 73 
17.9  Appendix H – Patient Satisfaction Questionnaire ...................................................................... 74 
18. Version History ............................................................................................................... .. 76  
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 9 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  2. Glossary 
Term Definition
ADL Activities of Daily Living
AE Adverse Event
BUN Blood Urea Nitrogen
CBC Complete Blood Cell Count
CD Crohn’s Disease
CE Capsule Endoscopy
CFR Code of Federal Regulations
CIP Clinical Investigation Plan
CRP C-reactive Protein
CTE Computed Tomography Enterography
Device deficiency Inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety, or performance. Device deficie ncies include 
malfunctions, use errors, and inadequate labeling.
DMC Data Monitoring Committee
DR Data Recorder
eCRF Electronic Case Report Form
eGFR Estimated Glomerular Filtration Rate
EC Ethics Committee
ED Emergency Department
EMA European Medicines Agency
FDA United States Food and Drug Administration
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 10 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Term Definition
FISP Fast Imaging with Steady -state Free Precession 
GCP Good Clinical Practice
GRE Gradient -Recalled Echo
GI Gastrointestinal
HIPAA Health Insurance Portability and Accountability Act
IBD Inflammatory Bowel Disease
IC Ileocolonoscopy
ICF Informed Consent Form
ICMJE International Committee of Medical Journal Editors
IDE Investigational Device Exceptions
IFU Instructions for Use; a manual or document accompanying a techn ical device 
that describes the directions by whi ch the device should be used
Investigative site An approved, participating study center/institution
InvestigatorIndividual member of the investigation site team designated and  supervised 
by the principal investigator at an investigation s ite to perform critical 
clinical -investigation-related procedures or to make important clinical 
investigation -related decisions.
NOTE An individual member of the investigation site team can al so be 
called “sub -investigator” or “coinvestigator”.
IRB Institutional Review Board
ISO International Organization for Standardization
IV Intravenous
MaRIA Magnetic Resonance Index of Activ ity
MITG Minimally Invasive Therapies Group
mITT Modified Intent -To-Treat
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 11 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Term Definition
MRE Magnetic Resonance Enterography 
MRI Magnetic Resonance Imaging
NPO Nothing by mouth –no food or liquids
NPV Negative Predictive Value
OC-RDC Oracle Remote Data Capture
PEG Polyethylene Glycol
PPV Positive Predictive Value
RDC Remote Data Capture
RCE Relative Contrast Enhancement
SAE Serious Adverse Event 
SB Small Bowel
SES-CD Simple Endoscopic Score for Crohn’s Disease
SF-ELS Sulfate -Free Polyethylene Glycol Electrolyte Lavage Solution
SSFSE Single -Shot Fast Spin Echo
WSI Wall Signal Intensity
WT Wall Thickness
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 12 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  3. Synopsis 
Title  Multicenter, prospective study comparing PillCam ® Crohn’s capsule endoscopy 
(CE) to ileocolonoscopy (IC) plus MRE fo r detection of active Crohn’s disease 
(CD) in the small bowel and colon in su bjects with known CD and mucosal 
disease (the BLINK study)  
Clinical Study Type  Multicenter, Prospective, Study  
Product Name  PillCam ® Crohn’s Capsule Endoscopy System  
Sponsor  United States:  
Medtronic MITG Early Technologies GI Solutions  
A Medtronic company (“Medtronic”)  
555 Long Wharf Dr,  
New Haven, CT 06511  
Phone: +(1) -(203)-562-1620 
 
Europe:  
Medtronic MITG Early Technologies GI Solutions 
A Medtronic company (“Medtronic”)  
Covidien Services Europe, Ltd.,  
Block G, First Floor  
Cherrywood Business & Technology Park  
Loughlinstown, Dublin 18, Ireland  
Phone: +(353) -(1)-439300 
 
Israel:  
Medtronic MITG Early Technologies GI Solutions 
(Given Imaging Ltd.)  
A Medtronic company (“Medtronic”)  
2 Hacarmel St. New Industrial Park  
POB 258, 20692 Yoqneam, Israel  
Phone: +(972)-(4)-909-7700  
Investigation 
Purpose  This study will evaluate the efficacy of  PillCam Crohn’s capsule endoscopy (CE) 
versus IC with MRE for detection of active  Crohn’s disease (CD) in the small 
bowel and colon in subjects with known CD and mucosal disease.   
Product Status  Post-market  
Primary 
Objective(s)  The primary objective of study is to asse ss the accuracy of CE versus IC plus 
MRE for detecting active CD, by visualizin g the small bowel and colon in subjects 
with known CD and mucosal disease.  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 13 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Secondary 
Objective(s)  xSpecificity, negative predictive value (NPV), and positive predictive (PPV) 
value for active CD in the small bowel and colon by CE as compared to IC 
plus MRE.  
xSensitivity, specificity, NPV, and PPV for active CD in designated bowel 
segments (proximal small bowel, term inal ileum, and colon) by CE as 
compared to IC plus MRE. 
x 
xPatient satisfaction  
x 
xConcomitant medication  
Other Planned 
Analyses    
  
 
Study Design  At baseline, subjects with known CD on routine clinical evaluation (e.g. history, 
physical exam, labs) and a history (within last 2 years) of mucosal disease 
(diagnosis based on radiologic, endoscopic,  histologic, or other clinical evidence) 
will undergo MRE, CE, and IC, to assess presence or absence of CD in the small 
bowel and colon.  
Study Location  United States, Israel, and Austria. Site s in the United States will include a 
minimum of 70% of total subjects; sites outside the US will be limited to 30% of subjects.
 
Sample Size  Up to 352 subjects.  
Planned study 
duration  Based on the number of sites and enrollmen t rate, study duration is expected to 
be up to approximately 1.5 years. The expected duration of each subject’s 
participation is approximately 3 months.  
Planned # of Sites  Up to 40 investigational sites.  
Video/Image 
Reading  Central readers will be used to read all videos/images and analyses will be based 
on these results. A consensus panel will be used if there are discrepancies in 
results between modalities at baseline. Capsule endoscopy and IC results will be 
read by gastroenterologists and MRE re sults will be read by radiologists.  
Inclusion/Exclusion 
Criteria  Inclusion Criteria: 
1.Subject has provided informed consent. 
2.Subject is ≥ 18 years of age. 
3.Subject is willing and able to comply with all aspects of  the treatment and 
evaluation schedule.  
4. Subject has known CD and a recent hist ory (within last 2 years) of mucosal 
disease (based on radiologic, endoscopic, or histologic evidence) OR known 
CD and active disease, based on cl inical judgment based on symptoms, 
laboratory data or other clinical information. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 14 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Exclusion Criteria: 
1.Subject has indeterminate, ulcerative , or antibiotic-associated colitis. 
2.Subject has stool positive for ova and parasite or for Clostridium difficile  
toxins within 3 months prior to enrollment. 
3.Subject with other known infectious cause of abdominal symptoms. 
4.Subject with clinical evidence of re nal disease within the past 6 months, 
defined as estimated glomerular filtrati on rate (GFR) outside of the normal 
reference range.  
5.Subject with known history of intestinal obstruction or current obstructive 
symptoms, such as severe abdominal pain with accompanying nausea or 
vomiting, based on investigator judgment. 
6.Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility. 
7.Subject with suspected or known bowel obstruction, stricture (defined as 
unequivocal proximal upstream dilation ≥ 2.5 cm) , or fistula. 
8.Subject has used non-steroidal anti-i nflammatory drugs including aspirin, 
two times or more per week, during the 4 weeks preceding enrollment. Low 
dose aspirin regimens ( ≤ 100 mg daily) are acceptable and not exclusionary. 
9.Subject suffers from any condition, such as swallowing problems, that 
precludes compliance with study and/or device instructions. 
10.Subject with cardiac pacemaker or ot her implanted electromedical device.  
11.Subject has any allergy or other know n contraindication to the medicat ions 
used in the study. 
12. Subject is pregnant (documented by a positive pregnancy test) or is actively 
breast-feeding. 
13. Subject is considered to be part of a vulnerable population (e.g. prisoners or 
those without sufficient mental capacity). 
14.Subject has known contraindication to MRE or IC. 
15. Subject has participated in a drug or de vice research study within 30 days of 
enrollment that may inte rfere with the subject’s safety or ability to 
participate in the study. 
16.Subject has any medical condition that would make it unsafe for them to participate, per the Investigator’s discretion 
17. Subject with ileostomy or colostomy, history of total or subtotal colectomy 
(including those with ileosig moidostomy, and ileorectostomy 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 15 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  4. Introduction  
4.1. Background  
Crohn’s disease (CD) is a chronic inflammatory bowe l disease (IBD) that has been a focus of attention 
due to its increasing incidence and prevalence around the world ( 1, 2). It involves any site of the 
gastrointestinal (GI) tract, but is most frequently localized to the terminal ileum and the proximal colon 
(3). Inflammation of the GI tract may ultimately le ad to stricturing or perforating complications ( 4). 
Symptoms of CD include abdominal pain, diarrhea, weight loss, nausea, and vomiting. Long-term 
management of CD can be achieved with immunosu ppressive or anti-inflammatory therapy, however 
most patients undergo repeated relapses and remission ( 5). 
Video capsule endoscopy was first approved for clinical  use in 2001 for the evaluation of the small bowel 
and has served to be an effective, noninvasive tech nique for imaging of the entire small-bowel mucosa 
(6). Contraindications for use of capsule endoscopy include history of bowel obstruction and known bowel 
strictures or swallowing disorders; and recent abdominal surgery ( 7). The Capsule Endoscopy System, 
PillCam® SB, PillCam® Crohn’s, PillCam® Patency Sy stem and PillCam® COLON 2, are all FDA cleared 
for the US market in patients aged ≥ 18 years and carry the CE mark fo r the European market in patients 
aged ≥ 8 years. The PillCam® Crohn’s Platform includes  1) the ingestible Croh n’s capsule, 2) Data 
Recorder (DR3), PillCam® Software, and 4) Given® Workstation. The Crohn’s capsule is specifically 
designed to image the small and la rge bowels. The Crohn’s capsule is a two-headed video capsule with a 
field of view of 172 degrees in each head and ha s a frame of rate up to 35 frames per second.  
The PillCam® Crohn’s capsules and the COLON 2 ca psules share hardware design, components and 
assembly and differ only in programming and operatio n mode, since the COLON 2 is designed to visualize 
the colonic mucosa while the Crohn’s capsule is inte nded for expanded visualization of the small bowel 
and the colon. The COLON 2 system has proven to be safe and effective in previous clinical studies ( 8-10) 
(ClinicalTrials.gov: [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]). Pre-c linical studies for the Crohn’s capsule have not 
been conducted, however clinical studies have been performed. To-date, there have been three 
performance studies that have assessed the Crohn’s capsule. One study included CD subjects 
(ClinicalTrial.gov: [STUDY_ID_REMOVED]), another study included  ulcerative colitis subjects (Clinical Trial.gov: 
[STUDY_ID_REMOVED]), and a third which included suspected or established IBD patients (Clinical Trial.gov: 
[STUDY_ID_REMOVED]). [STUDY_ID_REMOVED] study was a multi-center , prospective, controlled study, designed to 
establish the effectiveness of the PillCam® Crohn’s en doscopy platform as demonstrated by visualizing 
the small bowel and colon in subjec ts with active symptoms associated with CD. The primary objective 
was to evaluate the diagnostic yield of the Crohn’s capsule in the colon and terminal ileum compared to 
ileocolonoscopy (IC) ( 11). A total of 66 subjects with signs and symptoms of CD completed the study 
procedures and were included in the efficacy analys is.  The per-subject diagnostic yield rate was 83.3% 
for capsule endoscopy (CE) and 69.7% for IC. The yield difference was 13.6% (95% CI 2.6%-24.7%), 
with CE having a higher diagnostic yield rate for de tection of active CD. The Crohn’s capsule was also 
able to evaluate and detect active  CD in the more proximal small bowel, which cannot be reached by IC. 
There was only one device-related serious adverse event (bowel obstruction) reported, however the 
event resolved without sequelae. Since the comparison  of the two modalities in this study was limited 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 16 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  only to the terminal ileum and the colon, there is a need to evaluate the performance of the Crohn’s 
capsule in the entire small bowel and co lon compared to a gold standard.   
Clinical management of patients with known CD invo lves monitoring of disease activity for maintenance 
of clinical remission, early detection of relapse, and prevention of complica tions associated with the 
disease or treatment ( 12). Both the best measure of disease activity in CD and the measurement method 
are in question. Recent studies have shown that infl ammation of the intestinal mucosa is not firmly 
correlated with laboratory inflammato ry markers and patients’ symptoms ( 12-16 ). Mucosal healing, which 
is defined as restoration of normal mucosal appe arance and complete absence of ulceration and 
inflammation, is now considered an accept ed measure of disease activity in CD ( 12, 17). Evidence show 
that mucosal healing and deep remission are associ ated with improved long-term outcomes including 
reduced need for corticosteroid treatment, improved  quality of life, and reduction in complications 
requiring hospitalization or surgery ( 12, 18, 19).  
Ileocolonoscopy is currently the gold standard fo r mucosal disease evaluation in CD patients ( 20). There 
are limitations to this technique due to its invasi ve nature and possible requirement of analgesia and 
sedation ( 17). Ileocolonoscopy reaches only to the termin al ileum, thus eliminating evaluation of the 
more proximal small bowel. Even th ough the terminal ileum is the most  commonly affected area in the 
small bowel in CD, approximately half of the patients  with CD have lesions detected in the jejunum ( 21). 
The prevalence of jejunal lesions is higher in patien ts with terminal ileum disease and associated with 
increased risk of relapse; therefore evaluation of the entire small bowel is necessary for monitoring 
patients with CD. 
If proximal small bowel involvemen t is suspected, patients may rece ive examination with small bowel 
capsule endoscopy and/or balloon-assisted enteroscopy in addition to IC ( 20). Cross-sectional imaging 
techniques including magnetic resonance enterography (MRE) and computed tomography enterography 
(CTE) may also be used to evaluate the sma ll bowel, however these techniques have some 
disadvantages. Magnetic resonance enterography is co stly and CTE involves exposure to radiation; both 
techniques require intravenous (IV) contrast medium  and bowel distension with oral and/or rectal 
contrast. Since the PillCam® Crohn’s capsule is designed  to evaluate both the small bowel and colon, the 
device would eliminate the need of using two different techniques for evaluation of both segments in 
patients with CD ( 11). Capsule endoscopy is safe, noninvasive, and does not involve radiation exposure, 
therefore making it a preferable alternative modality for assessment of CD activity and evaluation of 
mucosal healing in patients with CD. 
4.2. Purpose   
This purpose of this study is to evaluate performa nce of the PillCam Crohn’s capsule [referred to as 
capsule endoscopy (CE)] as co mpared to IC with MRE. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 17 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  5. Objectives and Endpoints 
5.1. Objectives 
5.1.1. Primary Objective(s) 
The primary objective of this multicen ter, prospective study is to assess the accuracy of CE versus IC plus 
MRE for detecting active CD, by vi sualizing the small bowel and colon in subjects with known CD and 
mucosal disease.  
5.1.2. Secondary Objective(s)  
Secondary objectives include: 
1. Specificity, negative predictive value (NPV), and positive predicti ve (PPV) value for active CD in 
the small bowel and colon by CE as compared to IC plus MRE.  
2. Sensitivity, specificity, NPV, and PPV for active  CD in designated bowel segments (proximal small 
bowel, terminal ileum, and colon) by CE as compared to IC plus MRE. 
3. Patient satisfaction 
5.2    Endpoints 
 
5.2.1 Primary Endpoint 
The primary endpoint is the sensitivity for detecting active CD in the small bowel and colon by CE as 
compared to IC plus MRE. 
 
5.2.2 Secondary Endpoints 
 
The following secondary endpoints will be assessed: 
 
1. Specificity, negative predictive va lue (NPV), and positive predictive (PPV) value for active CD in the 
small bowel and colon by CE as compared to IC plus MRE (see Section 11.12.1).  
2. Sensitivity, specificity, NPV, and PPV for active  CD in designated bowel segments (proximal small 
bowel, terminal ileum, and colon) by CE as co mpared to IC plus MRE (see Section 11.12.1). 
3. Patient satisfaction (see Appendix I). 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 18 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  5.2.3 Safety Endpoints 
Adverse events (AEs) will be reported by number, se verity, and relationship to the study procedures 
(imaging modality, colonoscopy), as described in Section 11. The recording of AEs for all enrolled 
subjects will begin with the star t of baseline imaging procedures (MRE) and end 14 days following 
completion of the final baseline imaging procedure (IC) . Subjects with AEs at  14 days following the IC 
procedure will be followed for 30 days or until event resolves, whichever comes first.  
 
6. Study Design  
This is a multicenter, prospective study, evaluating the efficacy of CE versus IC with MRE for detecting 
active CD in the small bowel and co lon in subjects with known CD an d a recent history (within last 2 
years) of mucosal disease (based on radiologic, endo scopic, or histologic evidence) OR subjects with 
known CD and active disease based on clinical judgm ent based on symptoms, laboratory data or other 
clinical information. Subject populati on will include adult subjects (age ≥18 years). 
 At baseline, subjects with known CD on routine clinic al evaluation (e.g. history, physical exam, labs) and 
a recent history of mucosal disease (within last 2 years and diagnosis ba sed on radiologic, endoscopic, or 
histologic findings) OR subjects with known CD and active disease based on clinical judgment based on 
symptoms, laboratory data or other clinical informat ion will undergo MRE, CE, and IC, to assess presence 
or absence of CD across the small and large bowel.  
All CE and IC videos and MRE images will be evalua ted by central readers. CE and IC videos and MRE 
images will be randomly distribu ted among the central readers. 
The planned number of subjects is up to 352. A total of approximately 352 Crohn’s capsules will be 
utilized in this study.  
There are no procedures for the replacement of subjects. 
 
Other than known contraindications and precautions of the PillCam® Crohn’s system, described in the 
PillCam User Manual, there are no foreseeable facto rs that may compromise the outcome of the clinical 
investigation or the interpretation of results (e.g. ba seline characteristics, concomitant medication, the 
use of other study products, or subject-related factors such as age, gender or lifestyle). If any adverse 
occurrences are identifie d, they will be assessed, reported and documented.  
6.1. Duration 
Subjects will be enrolled at up to 40 clinical sites in  the United States, Israel, and Austria. United States 
sites will include a minimum of 70% of total subjects; sites outside the United States will be limited to 
30% of subjects. The minimum number of subjects enrolle d at each site participating in the study will be 
0 as enrollment is expected to be challenging and th ere is a possibility that an individual site will be 
unable to enroll any subjects. The maximum number of su bjects at each site will be 70 so that no more 
than 20% of the total study population will be enrolle d at any individual site. Expected enrollment is 1 
subject per site per month. 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 19 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  The planned number of subjects is up to 352. Ba sed on the number of sites and enrollment rate, study 
duration is expected to be up to approximately 1.5 year. The expected duration of each subject’s 
participation is approximately 3 months. 
6.2. Rationale  
This clinical study design was formulated in orde r to capture performance of the Crohn’s capsule as 
compared to IC with MRE. 
The combination of the two procedures (IC plus MRE) will allow evaluation of th e entire colon and small 
bowel and can be compared to the single procedure with CE.  
To-date, there have been few performance studies that have assessed the Cr ohn’s capsule. One study 
included CD subjects (ClinicalTrial.gov: [STUDY_ID_REMOVED]) ,another study included ulcerative colitis subjects 
(Clinical Trial.gov: [STUDY_ID_REMOVED]) and a third includ ed suspected or established IBD patients (Clinical 
Trial.gov: [STUDY_ID_REMOVED]). Results from [STUDY_ID_REMOVED] st udy demonstrated that the diagnostic yield rate 
for active CD in the terminal ileum and colon was hi gher with CE compared to ileocolonoscopy. However, 
due to the small sample size (66 subjects in efficacy  analysis), further studies are warranted to confirm 
these findings (11). Additionally, since the comparison of the two modalities in this study was limited only 
to the terminal ileum and the colon,  there is a need to evaluate the performance of the Crohn’s capsule 
in the entire small bowel and colo n compared to a gold standard. 
7. Product Description 
7.1. General 
The PillCam® Crohn’s capsule endoscopy platform is  comprised of four main subsystems: (1) an 
ingestible PillCam® Crohn’s capsule; (2) PillCam® Re corder (DR); (3) PillCam® Software (Version 9.0); 
and (4) Given® Workstation. The PillCam® Crohn’s capsule endoscopy platform includes the PillCam® 
Software, which is designed to focus on targeted pa thologies detected with the capsule, and an audio-
visual guidance platform integrated into the PillCam® Recorder that is intended to help guide the subject 
through the procedure. The PillCam® Crohn’s capsule plat form is fully compliant with all safety and radio 
standards and regulations similar to the currently  marketed capsule Endoscopy Systems. PillCam®  
Crohn’s has been approved for us e in the US, Euro pe and Israel.  
The device does not incorporate any medicinal produc t, human blood derivative or tissues of animal 
origin.  
The PillCam® Crohn’s capsule, specifically the caps ule outer envelope, will be in contact with human 
tissues or body fluids after ingestion.  
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 20 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  7.2. Dosage Form and Route of Administration 
The PillCam ® Crohn’s capsule is intended to be swallo wed by the patient (after appropriate bowel 
preparation and fasting) with a sip of water. Only one capsule will be ingested per endoscopy procedure. 
The device is intended to travel through the patien t’s gastrointestinal tract and be excreted naturally. 
 
7.3. Manufacturer 
PillCam® Crohn’s capsule endoscopy system is manufa ctured by Medtronic Minim ally Invasive Therapies 
Group (MITG) Early Technologies GI Solutions (formerly GIVEN Imaging). 
7.4. Packaging 
All equipment associated with the clinic al study will be identified with visible markings stating, “For clinical 
trial use only.” Labeling of device s will be provided in accordance with local language requirements. 
7.5. Intended Population 
The PillCam® Crohn’s capsule indications for use in US are:  
 
The PillCam® Crohn’s capsule is intended for visua lization of the small bowel and colonic mucosa.  
 • It may be used in the visualization and moni toring of lesions in the small bowel that may 
indicate Crohn’s disease not detected by upper and lower endoscopy, and for visualization of 
inflammation of the colon in patients wi th colonoscopy-diagnosed Crohn’s disease. 
 • It may be used in the visualization and monito ring in the small bowel of lesions that may be a 
 source of obscure bleeding (either overt or occu lt) or that may be potential causes of iron 
 deficiency anemia (IDA) not detected by initial upper and lower endoscopy.  
 • The PillCam® Crohn’s capsule may be used as a tool in the detection of abnormalities of the 
 small bowel and colon. It is intended for use in adults 
 
 
The PillCam® Crohn’s capsule indications for use in Europe and Israel are:  
 
The PillCam® Crohn’s capsule is intended for visua lization of the small bowel and colonic mucosa.  
 
 • It may be used in the visualization and monitori ng of lesions that may indicate Crohn’s disease.  
 
 • It may be used in the visualization and monito ring of lesions that may be a source of obscure 
 bleeding (either overt or occult).   
  • It may be used in the visualization and monitori ng of lesions that may be  potential causes of  
 iron deficiency anemia (IDA).   
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 21 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
   • The PillCam® Crohn’s capsule may be used as a tool in the detection of abnormalities of the 
 small bowel and colon. It is intended for use in adults and children from 8 years of age
 
7.6. Equipment 
7.6.1 PillCam® Crohn’s Capsule 
PillCam® Crohn’s capsule has been designed to achiev e more complete coverage of the small bowel and 
colonic mucosa, so its adaptive frame rate is set to ensure that images of bo th anatomical regions are 
captured for analysis. Features include: 
 
xOptics with super wide field of view (172 degrees for each imaging head). 
xHigher and adaptive frame rate (up to 35 frames per second). High frame rate is activated when 
the capsule enters the small bowel. 
 
The PillCam® Crohn’s capsule is provided as a single use disposable product. PillCam® Crohn’s capsule is 
ingested by the subject after bowel preparation, wi th a sip of water. The ca psule will be ingested a 
maximum of three times for the entire duration of th e study (ingestion at baseline and 6- and 12-month 
follow-ups for subjects randomized to  CE arm; ingestion at baseline only  for subjects randomized to IC 
with or without MRE arm. The capsul e will be ingested at baseline to ev aluate presence/absence of active 
CD in the small bowel and colon. At 6- and 12-month follow-ups, the capsule will be ingested to evaluate 
mucosal healing.  
7.6.2 PillCam Recorder (DR3) 
The new generation of PillCam® Recorder used in this study has enhanced communication features, 
computing power, and incorporates a Real-Time View ing screen. These modifica tions are detailed in the 
PillCam User Manual.  
7.6.3 PillCam Workstation 
The Workstation is a modified standard personal co mputer that is intended for reviewing the Pillcam® 
Software (Version 9.0) videos gene rated from the images acquired by the capsule, interpretation and 
analysis of the acquired data, and for generating reports. 
 
The software program used for video creation and inte rpretation has several useful features incorporated 
that aid the physician during the video review.  The PillCam® Crohn’s capsule is contraindica ted for use under the following conditions: 
xIn patients with known or suspected gastrointestinal obstruction, strictures, or fistulas based on 
the clinical picture or pre-procedure pre-ingestion testing and profile. 
xIn patients with cardiac pacemakers or other implanted electromedical devices. 
In patients with dysphagia or other swallowing disorders.  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 22 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  7.7. Product Use 
A member of the Medtronic Technical Support team  will install the PillCam Workstation at each 
participating research site and ensure  all equipment is fully functional.  Information regarding Instructions 
for Installation and Use can be found in the provided PillCam Endoscopy User Manual (US PillCam User 
Manual for sites in the US and Inte rnational PillCam User Manual for sites outside of the US). Specific 
instructions for Site Investigators for transferring vi deo images to the Core Imaging Lab will be provided 
separately. 
7.8. Product Training Requirements 
Gastroenterologists selected as Principal Investig ators participating in the clinical study and the 
associated clinical study staff will receive training on the device and system (including procedural use, 
device characteristics, shelf life and storage requirem ents, warnings, precautions, and contraindications).  
It is the responsibility of the Principal Investigator at each participating site to assure any staff performing 
tasks related to the clinical trial (Study Coordinators, Study Nurses, Radiologists, Gastroenterologist Sub-
Investigators, etc) have been properly trained, trai ning documented, and included on the Delegation of 
Authority Log. 
 For CE videos, central readers will be experienced gastroenterologists trained to read PillCam® Software 
videos. Experience and training are required in orde r to accurately interpret capsule endoscopy videos. 
The central readers will be trained by the Sponsor on  reading PillCam® Software videos. The training will 
include PillCam® version 9.0 software and PillC am® Software videos evaluation training.  
 Central readers will be expe rienced gastroenterologists for IC videos and radiologists for MRE images.  
 
7.9. Product Receipt and Tracking 
The Sponsor will initiate shipment of equipment to th e site upon receipt of all required documents (e.g., 
Site Qualification Report, fully executed Clinic al Trial Agreement). The site may not use the 
equipment/product or begin subject enrollment unt il IRB/EC approval is received and the Sponsor 
provides notification of Site Activation.  The Sponsor will maintain tracking for all shipment 
documentation. Prior to any shipment, the site w ill be informed by the Sponsor on the upcoming 
shipment, expected arrival date, and content of the shipment. The site should confirm receipt of the 
shipment and maintain shipping receipts.  
For each capsule, the appropriate Device Tracking and Device Identification electronic Case Report Forms 
(eCRFs) should be completed upon receipt and upon dispensing, respectively, by the site.  
 
7.10. Product Storage 
PillCam® Crohn’s capsule should be stored in an area where the temperatur e is controlled between 0-
25°C. As storage is at ambient temperature and PillC am Crohn’s capsule is a re adily marketed product, 
temperature logs are not required for BLINK; howeve r storage area should be locked/secure with access 
limited only to approved study staff to avoid use of the study device on non-trial patients. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 23 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
   
To avoid accidental activation (blinking) of the capsule while in its box:   
 • Keep the PillCam capsules in their box until use.  
 • Store the PillCam capsules only in th e packaging supplied with the product.  
 • Do not use a PillCam capsule if the packaging is damaged.  
 • Keep the capsule package away from strong magnetic fields (such as magnetic resonance 
 imaging [MRI] devices).  
 • Stack PillCam capsule boxes with the clear lid facing up only; never stack capsule boxes lid  
 to lid.  
 • Keep metal objects away from  the lid of the capsule box.  
 • After ingesting the PillCam capsule, instruct the patient not to sit on bare metal 
 surfaces, such as chairs with a metal sitting area, during the procedure. 
7.11. Product Return 
At the termination of the study, all unused study material must be returned with the corresponding 
documentation as directed by Medtronic. Any capsule th at reaches its expiration date before it has been 
dispensed should be returned to the Sponsor or dest royed on site; with proper documentation in either 
scenario.  The Device Tracking eCRF should be co mpleted once a capsule is dispensed, returned or 
destroyed.  
 
7.12. Product Accountability  
Good clinical research practice requires that investigators and research teams ensure accurate 
accountability for any device used in  a research study. It is expected that all devices will be used in the 
manner intended during the study, that they will be stored under appropriately controlled conditions and 
that they will be used only by (o n) subjects who have consented to participate in the research study. 
Access should be limited to designated study st aff only. Device accountab ility should be managed 
through the site’s completion of the Device Tracking and Device Identification eCRFs. 
 
Any device being used in clinical research must be strict ly accounted for and will not be shipped to any 
site unless all of the necessary approvals (e .g. Regulatory, IRB/EC) ha ve been received.  
 
This includes keeping records of:  
 1. Site receipt and in ventory management  
2. Storage  
3. Subject Disbursement  
4. Return (by Subjects and Center) and/or disposal  
It is the site’s responsibility to return the PillCam Workstation and Recorder to Medtronic within 30 days 
of the End of Study. 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 24 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  8. Selection of Subjects 
8.1. Study Population 
Subjects aged ≥18 years with known CD and mucosal disease. 
8.2. Subject Enrollment  
After being informed of the nature of the study, th e subject will sign a written informed consent form 
(ICF) that has been approved by th e Sponsor and the appropriate IRB/ EC  of the respective clinical site 
or the central IRB/EC during the screening visit. A subject is considered enro lled in the study when the 
ICF is signed and it is determined that all inclusio n/exclusion criteria are met. Inclusion/Exclusion may 
only be determined once screening lab results (C. Dificile, Stool O&P) and pregnancy test (as required) 
are reviewed.  Documented ICF will be collected prior to any data collection. See Section 11.4 for details 
on subject informed consent procedure.  
8.3. Inclusion Criteria 
1. Subject has provided informed consent. 
2. Subject is ≥ 18 years of age. 
3. Subject is willing and able to comply with all as pects of the treatment an d evaluation schedule.  
4. Subject has known CD and a recent history (withi n last 2 years) of mucosal disease (based on 
radiologic, endoscopic, or histologic evidence) OR known CD and active disease, based on clinical 
judgment based on symptoms, laboratory data or other clinical information. 
 
8.4. Exclusion Criteria 
1. Subject has indeterminate, ulcerati ve, or antibiotic-associated colitis. 
2. Subject has stool positive for ova and parasite or for Clostridium difficile  toxins within 3 months prior 
to enrollment. 
3. Subject with other known infectious cause of abdominal symptoms. 
4.Subject with clinical evidence of renal disease within the past 6 months, defined as estimated 
glomerular filtration rate (GFR) outside of the normal reference range.  
5. Subject with known history of intestinal obstructio n or current obstructive symptoms, such as severe 
abdominal pain with accompanying nausea or  vomiting, based on investigator judgment. 
6. Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility. 
7. Subject with suspected or known bowel obstruction, stricture (defined as unequivocal proximal 
upstream dilation ≥ 2.5 cm) , or fistula. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 25 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  8. Subject has used non-steroidal anti-inflammatory drugs including aspirin, two times or more per 
week, during the 4 weeks preceding enrollment. Low dose aspirin regimens ( ≤100 mg daily) are 
acceptable and not exclusionary. 
9. Subject suffers from any condition, such as sw allowing problems, that precludes compliance with 
study and/or device instructions. 
10. Subject with cardiac pacemaker or ot her implanted electromedical device.  
11. Subject has any allergy or other known contraindi cation to the medications used in the study. 
12. Subject is pregnant (documented by a positive pregnancy test) or is actively breast-feeding. 
13. Subject is considered to be part of a vulnerable population (e.g. prisoners or  those without sufficient 
mental capacity). 
14. Subject has known contraindication to MRE or IC. 
15. Subject has participated in a drug or device rese arch study within 30 days of enrollment that may 
interfere with the subject’s safety or ability to  participate in the study. 
16. Subject has any medical condition that would mak e it unsafe for them to participate, per the 
Investigator’s discretion 
17. Subject with ileostomy or colostomy, history of total or subtotal colectomy (including those with 
ileosigmoidostomy, and ileorectostomy 
 
9. Study Procedures  
9.1. Schedule of Events 
Table 1:  Study schedule and Site Collection Data 
 
 Screening 
(No more than 30 days prior to first 
Baseline Procedure - MRE) Baseline Procedures  
1, 2 
Informed consent1 X  
Eligibility criteria  X  
Demographics  X  
Montreal classification3 X  
Medical history X  
Previous GI procedures  X  
Surgical history  X  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 26 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Laboratory tests4, 5 X X 
Pregnancy test4, 5 X  
Concomitant medications   X 
PillCam® patency test   X 
IC, MRE AND PillCam® Crohn’s1  X 
Patient satisfaction6  X 
Adverse events   X 
Study deviations X X 
Study exit   X 
1. Informed consent may be collected more than 30 da ys prior to first baseline imaging procedure – MRE. 
2. All baseline imaging procedures (MRE, pate ncy capsule [if needed], CE, and IC) need  to be performed within 4 weeks. If 
MRE demonstrates a stricture with unequivocal upstream dilatation  of at least 2.5cm, then the subject must be exited from 
further study participation.  If any other stricture is identified on MRE, or there is clinical suspicio n that the PillCam Crohn’s 
capsule will not be excreted naturally , then a patency capsule procedure needs to be pe rformed. IC will take place on the same 
or following day after CE .                                                                               
3. See Appendix A for more details.                                                                                                                                   
4. See Appendix B for a complete listing of tests to be performed.   
5. Please note that Screening Laboratory results for Stool O&P, C. Difficile and pregnancy test are required to determine subject 
inclusion/exclusion.  Screening Laboratory results MUST be evaluated prior to enrolling a subject in th e trial.  Baseline labs 
must be collected and results reviewed within 14 days prior to MRE.                                                                       
6. The patient satisfaction questio nnaire will be completed by subjects after the la st baseline procedure (I C) in person or via 
phone on the same or next business day of IC procedure completion .        
 
9.2. Subject Consent 
Informed consent will be obtained before any study-sp ecific procedures are initiated or data collected. 
Principal Investigator or his/her authorized designee will conduct the informed consent process. 
 
At the screening visit, subjects w ill be approached to obtain written informed consent prior to any data 
collection. Once the ICF is collected, screening of subject will follow. The purpose of the study and the 
benefits and risks of the procedur es will be explained to the subjec t and the consent process must be 
documented accordingly in the medical record. Subjec ts who agree to study pa rticipation must sign a 
Sponsor and IRB/EC-approved ICF. Consent to participat e in this study must be given in writing. Subjects 
that are unable to give consent will not be included in study. 
 
Informed Consent will be obtained in accordance with the CFR Title 21, Part 50 (US) or ISO14155:2011 
(Austria and Israel) as well as the Declaration of He lsinki. The Investigator or designee must obtain 
written informed consent before any clinical study re lated activity takes place. Prior to entry into the 
study, the IRB/EC and Medtronic-approved ICF form, and the Health In surance Portability and 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 27 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Accountability Act (HIPAA) Authorization Form (US only) will be given to each subject. The Investigator or 
designee will fully inform the subject of all aspects of the clinical study that are relevant to the subject’s 
decision to participate in the clinical study (e.g. pu rpose and duration of the study, requirements of the 
subject during the study, potential risks and possible be nefits associated with participation in this study). 
All items addressed in the Informed Consent Form mu st be explained. The language used shall be as 
non-technical as possible and must be understandable to the subjects. 
 The subject must have ample time and opportunity to  read and understand the Informed Consent Form, 
to inquire about details of the clinical study, and to decide whether or not to pa rticipate in the clinical 
study. All questions about the clinical study should be answered to the satisfaction  of the subject.  In the 
case that a subject is unable to read, an impartial witness must also  be present and sign the informed 
consent to confirm that the research has been clearl y explained and all of the subject’s questions have 
been answered. 
 
Neither the Investigator, nor the investigation site st aff shall coerce or unduly influence a subject to 
participate or to continue to partic ipate in the clinical st udy. The informed consent process shall not waive 
or appear to waive the subject’s rights. 
 
When the subject decides to particip ate in the clinical study, the HIPA A Form (US only) and the Informed 
Consent Form must be personally signed and dated by the subject 
 
After all persons have signed and dated the Informed  Consent Form, the Investigator must provide the 
subject with a copy. 
 Medtronic will inform the Investigators whenever info rmation becomes available th at may be relevant to 
the subject’s confirmed participation in the clinical study. The Investigator or his/her authorized designee 
should inform the subject in a timely manner. 
 
Medtronic will revise the written Informed Consent Form whenever new inform ation becomes available 
that may be relevant to th e subject’s confirmed particip ation in the clinical study. The revised information 
will be sent to the Investigator for approval by the IRB/EC. After approval by the IRB/EC, a copy of this 
information must be provided to the participatin g subjects, and the informed consent process as 
described above needs to be repeated. 
 
If the ICF is amended during the course of the study, the IRB/EC will determine: 
  • Whether or not active subjects should be re-consented at their next visit and 
 • Whether or not subjects who have completed the study at the time of the amendment should 
 repeat the informed consent process. 
 
Subjects will be informed that qualified personne l from the investigational center, the Sponsor 
(Medtronic), agencies such as the FDA/local regulatory  authority in Europe (Austr ia) and Israel and/or the 
IRB/EC may have access to clinic records that reveal their identity. 
 
The investigational center must report th e following violations to their IRB/EC: 
 
 • Failure to obtain informed consent from subject. 
 • Failure to obtain informed consent prior to performing one or more study procedures. 
 • Failure to maintain ICFs on file for all subjects who have provided informed consent. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 28 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
   • Use of an ICF that has not received appr oval from the IRB/EC.             
 • Use of an incorrect version of the ICF. 
9.3. Subject Screening  
All subjects must be properly consented prior to any screening and/or baseline procedures.  Once 
consented, a screening visit will be pe rformed within 30 days prior to baseline procedures to assess pre-
procedure eligibility. In the event that the screening and eligibility a ssessment takes place more than 30 
days prior to the planned procedure date, the Inve stigator should contact the subject prior to the 
procedure date to assure there is no chan ge in the subject’s medical condition.  
 
Screening visit  (No more than 30 days prior to first Baseline Procedure - MRE) - the following 
assessment will be performed at scre ening and the results will be reco rded on the appropriate subject 
eCRFs:  
 
xInformed consent (may be comp leted >30 days prior to MRE) 
xInclusion/Exclusion criteria 
oPlease note evaluation of results of severa l Screening Laboratory tests (Stool O&P, C. 
Difficile, pregnancy) is required to assess Inclusion/Exclusion criteria.   
xDemographics – including gender, year  of birth, height, and weight.  
xMontreal classification – see Appendix A. 
xMedical history – relevant (related  to inclusion/exclusion criteria) medical historywithin the last 2 
years will be assessed including recent history of mucosal dise ase, history of swallowing 
problems, history of intestinal stricture, presen ce of implanted electromedical device, any known 
allergies, current GI symptoms (e.g. obstructive symptoms, history of gastroparesis) or other GI 
motility disorder, contraindication to MRE or IC , and enrollment in any other drug/device study 
within 30 days.  
xPrevious GI procedures – all previous IBD–relate d procedures within the last 5 years (including 
but not limited to IC, MRE, CTE, capsule endoscopy, esophagogastroduodenoscopy), including 
date and results from the last procedure will be documented. 
xSurgical history – other GI-related surgical procedures not captured under ‘previous GI 
procedures.’ 
xPrior and concomitant medications – All current medi cations, including type and dose, need to be 
reported. Subject will be excluded from the st udy if he/she has used non-steroidal anti-
inflammatory drugs including aspirin, two times or more per week, during the 4 weeks preceding 
enrollment. Low dose aspirin regimens ( ≤100 mg daily) are acceptable and not exclusionary.  
Additionally, subjects must not use NSAIDs includ ing aspirin, two times or more per week, from 
the time of enrollment until comple tion of the IC procedure.   
xLaboratory tests – See Appendix B. 
xPregnancy test – see Appendix B. 
xStudy deviations 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 29 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
   
A subject is considered enrolled in the study when the ICF is signed (See Section 11.4 for details) and it 
is determined that all inclusion/exclusion criteria ar e met. Documented ICF will be collected prior to any 
data collection. Subjects who provide study consent, bu t then are determined to be  ineligible prior to the 
MRE procedure at baseline will be considered a screen  failure and will not require additional study follow-
up visits. The reason for the screen failure w ill be clearly captured on the applicable eCRFs.  
9.4. Baseline 
All baseline procedures must be comp leted within 4 weeks (completion of MRE to completion of IC).  All 
baseline labs must be completed prio r to, but no more than 14 days before, MRE. Subjects will first 
undergo MRE evaluation as outlined in Appendix C. If  MRE shows evidence of a stricture with unequivocal 
proximal upstream dilation ≥ 2.5 cm, based on local reading results,  then the subject will be exitedfrom 
the study. If any other stricture is identified on MR E, based on local reading, or if there is clinical 
suspicion that the PillCam Crohn’s capsule will not be excreted naturally, then 
the subject must  undergo a Patency procedure before proceeding with the CE pr ocedure and then the IC 
procedure, all within 4 weeks after the MRE..  
 Subjects whose patency cannot be confirmed through either the baseline MRE procedure or capsule 
patency study will be disc ontinued from the study. 
 
Prior to the CE procedure, subjects will be instru cted to perform the bowel preparation procedure and 
follow a detailed dietary regimen. All sites and subj ects will follow the same preparation procedure as 
outlined in Appendix E1 for the CE procedure.  
 
Following completion of the CE procedure (either th e same or following day), the subjects will undergo 
an IC procedure with intubation of the terminal ileum, if possible. In case the IC procedure follows the CE 
procedure on the same day, it is recommended to st art the CE procedure early in the morning. If the IC 
procedure is done the following morn ing, the subject will stay on clear liq uid diet (or NPO, if required per 
physician’s discretion for sedation) and receive additional preparation per physician discretion. Day 0 will 
be in reference to the last day of  baseline procedures, which will be the day of completion of IC.  
 
Baseline visit  - the following assessment will be performed at baseline and the results will be recorded 
on the appropriate subject eCRFs: 
xLaboratory tests– see Appendix B 
xConcomitant medications: 
At baseline subjects must not use NSAIDs incl uding aspirin, two times or more per week, 
during the 4 weeks preceding CE, IC and MRE procedures. Low dose aspirin (<100 mg 
daily) regimens are acceptable and not exclusionary. 
  All current medications, including type and dose, need to be reported 
  Need to specify related/no n-related medication for CD 
xPatient satisfaction – see Appendix I. At baseli ne, questionnaires will be completed by subjects 
after IC. If subjects are unable to complete the questionnaires immediately following IC due to 
sedation, appropriately de legated research staff may interview the subject by phone the following 
day in order to obtain the subject’s responses. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 30 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xAdverse events 
xStudy deviations  
9.5. Medication Compliance 
Subjects will take a preparation for CE, IC, and MR E. The CE system has a regimen alert system to 
remind subjects to take the prescribed preparation materials. There will also be medications taken by 
subjects as prescribed by their respective physicians  to treat Crohn’s disease. The medication usage will 
be tracked in appropriate eCRFs. 
9.6. Magnetic Resonance Enterography 
Sites may be asked to submit sa mple imaging studies to the Imag ing Core Lab. The sample cases 
demonstrate that local site can follow the study protocol for the MRE procedure before subject 
recruitment begins. If there are errors in the sample imaging studies, corrections need to be made before 
enrollment begins.  
 
MRE will be performed by local radiologists with expe rience in conventional an d GI MRI who have been 
properly trained to the study protocol and included  on the Delegation of Authority Log. MRE procedure 
must be performed in alignment with Appendix C an d the BLINK Imaging Manual.  A 1.5T or 3T whole-
body MRI unit will be used. All sites and all subjec ts will follow the same procedure as outlined in 
Appendix C for MRE.   
 
The MRE images must be uploaded and transferred to  the Imaging Core Lab (ICON) within 48 hours of 
completion of the procedure, based on instructions provided.  
9.7. PillCam Patency Study 
If a stricture with unequivocal upstream dilation of at least 2.5cm is evident on baseline MRE (based on 
local read), then the subject must be exited from furthe r participation in the study.  If any other stricture is 
evident on baseline MRE, or there is  clinical suspicion that the PillCam Crohn’s capsule will not be excreted 
naturally, then a PillCam Patency procedure (Appendix D) should be performed prior to the baseline CE 
procedure.  
9.8. Capsule Endoscopy Procedure 
Subjects will be instructed to perform a preparation procedure and follow a detailed dietary regimen prior 
to and during the CE procedure. All preparation produc ts will be standard GI cleansing products approved 
by FDA and European Medicines Agency (EMA). All si tes and all subjects will fo llow the same preparation 
procedure as outlined in Appendix E1 for the CE procedure.  
 CE procedure must be performed per instruction provided in Appendix E1 and the BLINK Imaging 
Manual.  During the CE procedure, subjects will be asked to use a Subject Instructions Form (Appendix 
E2) to document their activities. This form will be  used to document the subject’s adherence to the 
procedure steps. The Subject Instructions Form will al so serve as source data for eCRF entries. Trained 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 31 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Medtronic personnel may be present at the capsule inge stion and at study follow-up visits. The role of the 
Medtronic person is to gi ve technical support only. 
 All CE videos and raw data files will be downloaded to  the PillCam work station an d then saved in a digital 
format on the provided external hard drive. The CE video files must be uploaded and transferred to the 
Imaging Core Lab (ICON) within 48 hours of the co mpletion of the procedure, based on instructions 
provided in the BLINK Imaging Manual.  The raw data files should be maintained  on the external hard 
drive and will be collected by  Medtronic personnel.   
9.9. Ileocolonoscopy 
The IC will be performed on the same or following da y after the CE procedure. To avoid repetitive bowel 
preparation for subsequent colonoscopy, the CE bowel preparation (Appendix E1) is to be followed at 
baseline. If IC is done the following day, the subj ect will stay on clear liquid diet (or NPO, based on 
physician’s discretion for sedati on) and receive additional preparation per physician discretion. 
 
Prior to discharge, the subject will be instructed to  notify study staff in case of any abdominal pain, 
vomiting or other GI problems. 
 The IC examination will be recorded in digital fo rmat. The site number and subject number (NOT name) 
should appear in the recorded video either by insert ing the information to the recording or by taking a 
video recording at the beginning of the procedure video with the endoscope of the site and subject 
number written on a piece of paper.  
 
All IC videos will be saved in a digital format (an ex ternal hard drive will be provided, if necessary). The 
IC videos must be sent to the Imaging Core Lab (ICO N) within 48 hours, based on instructions provided. 
9.10. Central Reader Image/Video Reading 
All CE and IC videos and MRE images will be randomly  distributed to and evalua ted by central readers at 
an Imaging Core Lab.  Central readers will be blinded to the si te and subject from which the 
videos/images they are assigned originate. 
 
All study analyses will be based on the results of th e central readers. A consensus panel will be used if 
there are discrepancies in results between modalities at baseline.  
In cases when an imaging modality is not available for a given segment (small bowel, TI, and/or colon), 
that modality will be considered “null” for the segm ent and will not be used to assess modality agreement 
or disease activity for the segmen t.  The available modality or moda lities will be reviewed by central 
readers and (if necessary) the Consen sus Panel and used to assess disease activity in these cases.  
 
Detailed instructions will be provided to sites for tr ansferring videos/images to the Imaging Core Lab via 
the BLINK Imaging Manual.  Detailed reader instructio ns will be provided to the central readers via the 
Imaging Core Lab. All central reader s must read each video or image independently without input from 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 32 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  other readers, investigators, or other site staff. Each reader will produce an independent report (CE 
Readers) and complete appropriate eCRFs fo r each video or image assigned to them. 
 
9.10.1 Imaging Scores for Central Reading 
Active CD, and subtle (defined as ulcers ≤ 5mm) lesions will be assessed with central reader results 
across the three modalities.  
 Presence of active CD in the proximal small bowel,  terminal ileum, and colon will be assessed at baseline 
(see Appendix G for more details). The scores de tailed below will be used to compare the accuracy 
(sensitivity, specificity, NPV, PPV) of CE and IC plus  MRE in the identification of active CD in the small 
bowel and colon. The combination of all three proc edures (MRE, CE, and IC) will serve as the gold 
standard.  
 Additionally, subgroup analyses will be performed to co mpare the accuracy of CE and IC plus MRE in the 
following designated bowel segments: proximal sma ll bowel, terminal ileum, and colon. The following 
procedures will serve as the gold standard in the designated bowel segments: MRE+CE in the proximal 
small bowel, MRE+CE+IC in the terminal ileum, and CE+IC in the colon. 
 
Capsule Endoscopy Scores: 
 The scores used for identification of active CD  will be the Lewis score (Appendix H1) and Simple 
Endoscopic Score for Crohn’s Disease Index (SES-CD) (Appendix H2) for CE. The Lewis score will be used 
to evaluate active CD in the prox imal small bowel and the SES-CD will be used for the terminal ileum and 
colon.  
 Ileocolonoscopy Score: 
 
The score used for identification of active CD will be the SES-CD (Appendix H2) score for IC. SES-CD 
score will be used to evaluate active CD in the terminal ileum and colon.  
 MRE Score: 
 
The score used for identification of active CD will be the Magnetic Resonance Index of Activity (MaRIA) 
score for MRE (Appendix H3). The MaRIA score will be used to evaluate active  CD in the small bowel 
(proximal and terminal ileum). 
 
 
 
    
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 33 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Table 2:  Central Reader Collection Data  
 
 Screening 
 Baseline 
Procedures  
 
Presence of Active CD1  X 
Subtle lesion   X 
Bowel cleansing level 
scale2  X 
1. Presence of active CD will be  used to calculate accuracy 
measures comparing CE to IC plus MRE . Active CD will be 
assessed based on the following scores: the Lewis score (see 
Appendix H1) will be used to ev aluate the proximal small bowel 
with CE; the SES -CD scores (see Appendix H2) will be used to 
evaluate both the terminal ileum and colon with CE and IC;  and 
the MaRIA (see Appendix H3) scor e will be used to evaluate the 
small bowel (proximal and terminal ileum) with MRE.                      
2. Following bowel preparation, the bowel cleansing level scale as 
detected with CE (see Appendix E4)/IC (see Appendix F3) will be 
collected.  
 
9.11. Assessment of Efficacy 
Data for accuracy of CE versus IC plus MRE for de tecting active CD will be collected and evaluated by 
central readers after all baseline procedures (MRE, CE, and IC) have been co mpleted.  All CE and IC 
videos and MRE images will be rand omly distributed to and evaluated by central readers. Presence of 
active CD will be used to calculate accuracy measures  comparing CE to IC plus MRE. Active CD will be 
assessed based on the following scores: the Lewis scor e (see Appendix H1) will be used to evaluate the 
proximal small bowel with CE; the SES-CD scores (see  Appendix H2) will be used to evaluate both the 
terminal ileum and colon with CE  and IC; and the MaRIA (see Append ix H3) score will be used to 
evaluate the small bowel (proxima l and terminal ileum) with MRE.  See Section 9.13.1 for details on 
imaging scores for central reading.  
 
Each reader will produce an independent report (C E readers only) and complete appropriate eCRFs for 
each video or image assigned to them.  
 
9.12. Assessment of Safety 
Type, incidence, severity, duration, and procedure/de vice relationship of adve rse events (AEs) will be 
collected. AEs for all enrolled subjects will be collect ed from the start of baseline imaging procedures 
(MRE) and end 14 days after completion of the last  imaging procedure (IC).  Subjects with AEs at 14 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 34 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  days after the IC procedure will be followed for 30 da ys or until event resolves, whichever comes first. 
Adverse event data will be collect ed and reported on eCRFs.  
For safety analyses, adverse events will be su mmarized using frequency counts and percentages. 
Descriptive statistics will be provided by study arm and by severity and relationship, according to the 
definitions in Section 11. Between groups comparison  will be performed by Chi- square test or Fisher’s 
exact test as appropriate .Individual listings of adverse events, (including modifications and deleted 
events), including event type, star t date, duration, severity, and device-relatedness will be provided as 
appropriate. 
9.13. Recording Data 
This study will utilize an electronic database and eC RF. All data requested on the eCRF are considered 
required. Data points not collecte d and/or recorded will be consid ered deviations unless otherwise 
specified. Procedures used for data review, database cleaning, and issuing/resolv ing data queries will be 
included in the Data Management Plan.  
 
The Principal Investigator must ensure the accuracy  and completeness of the recorded data and then 
provide his/her signature on the appropriate eCRFs. The Investigator’s electronic signature for specific 
eCRFs will be documented in complian ce with local regulations. Changes to data previously submitted to 
the Sponsor will be reviewed for po tential AE and complaint data and will require a new signature by the 
Investigator to acknowledge/approve the changes. 
 
Visual and/or computer data revi ew will be performed to identify possible data disc repancies.  Manual 
and/or automatic queries will be crea ted in the Oracle Remote Data Capture (OC-RDC) system and will be 
issued to the site for appropriate response. The site staff will be responsible fo r resolving all queries in 
the database. 
 
This study will be using a 21 CFR Part 11 compliant electronic data capture system. All system level 
validation documentation is retained wi thin the Information Systems group. 
9.14. Deviation Handling 
No changes to the protocol will be permitted withou t the written approval from Medtronic, the IRB/EC, 
and Competent Authority. The investigator is not allo wed to deviate from the Clinical Investigation Plan 
(CIP), except under emergency circ umstances to protect the rights, safety and well-being of human 
subjects. The investigator must notify Medtronic and the reviewing IRB/EC of any deviation, which will be 
recorded in the eCRF, from the CIP when specific to the protection of the life or physical well-being of a 
subject in an emergency. Such notice must be given as soon as possible, but in no event later than 5 
working days after the emergency has occurred. Except in such an emergency, prior written approval by 
Medtronic is required for changes in or deviations from  the CIP. If these changes or deviations affect the 
scientific soundness of the CIP or the rights, safety, or welfare of human subjects  the IRB/EC will also be 
notified. All other deviations will be reported per the site’s IRB/EC deviation policy. Should any deviations 
from the CIP occur, these will be reviewed by Medtro nic for their clinical sign ificance. If the event is 
performed without written approval fr om all parties, the investigator may be terminated from the study. 
Corrective and preventive actions and principal investig ator disqualification will be included in the Clinical 
Study Management Plan and/or Monitoring Plan. If further escalation is n eeded, it may result in 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 35 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Corrective and Preventive Action (CAPA), suspension, or  termination. If it is determined that there is 
investigator fraud, or strong evidence of fraud, the course of action may include, but is not limited to: 
potential exclusion from analyses, site closure, notifica tion of the responsible IRB/ EC of the actions to be 
taken, notification of key stakeholders and/or study team of the actions to be taken, notification of appropriate regulatory authority(ies) and/or restrict ions on future participation in clinical studies.
 
9.15. Subject Withdrawal or Discontinuation  
The reason for study exit, including screen failure, will  be documented on the applicable eCRF and in the 
subject file. The Sponsor must be in formed of each withdrawal case.  
 
In the event the subj ect withdraws consent during the study, the date of withdrawal will be documented. 
Individual subjects will not be replaced.   
If the Investigator voluntarily removes a subjec t from further study participation, supporting 
documentation must be in place for the rationale an d date of removal. The Investigator may withdraw a 
subject from the study at any ti me for the following reasons: 
 
xSevere side effects clearly related to the study procedures 
xPresence or appearance of exclusion criteria 
xAppearance of accompanying diseases renderin g further participation in the study impossible 
xA significant protocol violation, as determined  either by the Sponsor or the Investigator 
xSubject noncompliant with procedures 
xSubject noncompliant with visits 
xAt the specific reasonable request of the study Sponsor 
 
For Austria and Israel only: If pati ent withdrawal is due to problems related to the device safety or 
performance, the Investigator shall ask for the subjec t's permission to follow his/her status/condition 
outside the clinical investigation. 
Every attempt will be made to contac t subjects that are noncompliant wi th study visits Subjects will be 
considered lost to follow-up once the following steps have been taken: 
xTwo phone calls should be made to the subject.  Each attempt should be clearly documented in 
the source documents and the response or  lack thereof should be captured.   
xIf there is no response to the ph one calls, then an official, certifie d letter should be written to the 
subject.  A copy of the letter and return or deliv ery receipts should be re tained in the subject’s 
source document. 
 
When all due diligence attempts to contact have been  made, after a period of two (2) weeks, the subject 
will be considered Lost to Follow-up. The Sponsor should be notified and the End of Study (EOS) form 
should be completed.
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 36 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  10. Risks and Benefits 
10.1. Potential Risks 
For female subjects that ar e pregnant or have childbearing potential, there may be risks to the subject or 
unborn child that are not yet known. 
There may be additional risks related to this study (o ther than those listed here ) that are not yet known. 
Risks must be continuously monitored, asse ssed and documented by the Investigator. 
 
10.1.1 PillCam® Crohn’s Capsule 
Possible Risks associated with use of the PillCam® Cr ohn’s capsule, include but are not limited to the 
following: 
xNausea 
xVomiting 
xDiarrhea 
xAbdominal pain 
xHeadache 
xVertigo 
xDifficulty or inability to swallow the capsule 
xAsymptomatic capsule retention 
xFatigue 
xCapsule aspiration 
xCapsule retention or delayed excretion 
xPhysical intervention, which could incl ude surgery, to remove the capsule 
xObstruction 
xPerforation 
xMucosal injury or bleeding 
xSmall bowel obstruction  
 
Implanted electronic devices such as, but not limited to, pacemakers, neurostimulators, implantable 
cardioverter defibrillators, ventricular assist devices, spinal cord stimulators, cochlear implants, infusion pumps, 
and bone growth stimulators may be influenced by interference produced by PillCam® Crohn’s.  
 
10.1.2 MRE 
Although the MRE examination poses almost no risk to the average patient when appropriate safety 
guidelines are followed; there are still risks which include, but are not limited to the following: 
xPossibility of excessive sedation, if used. 
xNephrogenic systemic fibrosis (thickening and scarring  of connective tissue in the skin, joints, eyes, 
and internal organs)  
xAllergic reaction if contrast material is injected. If subject experience allerg ic symptoms, a radiologist 
or other doctor will be available for immediate assistance. 
xNausea 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 37 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xVomiting  
xAbdominal pain 
xBlurry vision 
xDry mouth 
xTachycardia 
xElectrolyte disturbance 
xDehydration 
xKidney injury 
xFluid retention 
xHypotension, hypertension or vasovagal reaction 
 
10.1.3 Ileocolonoscopy 
 
Possible risks associated with Ileocolonoscopy, include but are not limited to the following: 
xCramping  
xPain 
xBloating 
xDiarrhea 
xNausea 
xVomiting  
xAbdominal swelling  
xPerforation, infection, or bleeding to the intestinal wall 
xPostpolypectomy syndrome 
xUndetected abnormalities 
xAllergic reaction to sedation 
xRespiratory depression, hypoxia, chest pain, cardiac arrhythmias 
xHypotension or hypertension , and vasovagal reactions 
xFluid retention  
xKidney injury 
10.2. Potential Benefits 
Professional guidelines for the management of Croh n’s disease have recommende d ongoing monitoring of 
disease activity with tools such as those used in this study (22). A “treat to target ” strategy is increasingly 
recommended to tailor therapy based on mucosal evid ence of disease (23). T hus, subjects may benefit 
from results of diagnostic tests performed during the study as treating physicia ns may be able to make 
more informed decisions in the care of subj ects based on results of study procedures.  
The information from this study may benefit other subjects with CD in the future. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 38 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  10.3. Risk-Benefit Rationale 
This study will include up to 352 subjects, aged 18 years and older, that have known CD and mucosal disease. 
Subject may be female or male. All study procedures  are part of the standard medical management of 
patients with Crohn’s disease. The risks to subjects would be similar to the expected risks to Crohn’s disease 
patients in standard medical practice. MR enterography has been advocated to be very useful in the assessment of mucosal disease without endoscopy but its utility is limited to the small bowel. The PillCam® 
Crohn’s capsule has the advantage of being able to assess both the small bowel and colonic mucosa in a 
single examination, which has the potential to reduce time, expense and inconvenience to the subject. This 
study is designed to evaluate the ability of the Crohn’s capsule to assess mucosal disease with MRE and 
ileocolonoscopy.   
The risks for MRE, as noted, will be minimized by exclud ing subjects who have evidence of renal insufficiency. 
This should service to greatly reduce the potential for nephrogenic systemic fibrosis. In addition, subjects with 
sensitivity to substances used in the course of the MRE, or during the preparation for the CE and IC 
procedures will be excluded.  Sedation will be performed only in accredited facilities by qualified personnel and the ileocolonoscopy will be performed by board certified gastroenterologists to decrease the risk to study 
subjects.  
 
Retention of the Crohn’s capsule will be minimized since capsule will be administered only to those subjects 
who have demonstrated patency of the gastrointestinal tract by MRE.  MRE has shown to be an effective 
predictor of safe passage of the video capsule (24). Also, investigators have the option of using the Patency 
capsule to determine whether the video capsule will be excreted. Patency capsule is useful in identifying patients that can undergo capsule enteroscopy without risks of capsule retention (25).  
 
Subjects with swallowing disorders are excluded to avoid the risk of capsule aspiration or inability to 
swallow the capsule. Known side effects of the purgatives used for the preparation for capsule endoscopy 
and colonoscopy will be minimized by allowing bo th procedures to be pe rformed with a single 
preparation.
 
11. Adverse Events and Device Deficiencies 
11.1. Definitions/Classifications 
Adverse event definitions used in this study are based on ISO 14155:2011 (Clinical Investigation of 
Medical Devices for Human Subjects -- Good Clinic al Practice), which is aligned with MEDDEV 2.7/3 
Revision 3, May 2015 (Guidelines on  Medical Devices, Clinical Inve stigations: Serious Adverse Event 
Reporting).  
 
 Events will be collected for all en rolled subjects with the start of ba seline imaging procedures (MRE) and 
end  14 days following completion of the IC procedure. Subjects with AEs  14 days following the IC 
procedure will be followed for 30 days or until event re solves, whichever comes first.  During the course 
of the study, the following AEs will be collected and reported on the eCRF: 
 
xAll AEs related to PillCam® Crohn’s  
xAll AEs related to IC 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 39 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xAll AEs related to MRE 
xAll AEs related to bowel preparation 
xAll device deficiencies  
xAll SAEs 
 
The following should not be considered an AE:  
xA condition requiring a preplanned procedure un less the condition worsened since screening. 
xA preexisting condition found as a result of sc reening, unless the condition has worsened since 
enrollment. 
 
 
For purposes of this protocol, the following occurrences are considered to be expected 
observations and will not be considered AEs, as long  as the event is not asso ciated with significant 
sequelae, does not prolong hospitalization, and responds to standard medical therapy:  
 
xTransient nausea, diarrhea, vomiting, headache or  abdominal pain that is determined to be 
related to one of the study procedures (including  the preparation) and that resolves within 48 
hours without extended hospitalization (>24 hours). 
 
All responses to the above events that requi re treatment beyond the institution’s standard 
procedures will be reported as AEs. 
 
11.1.1 Adverse Event (AE) 
An AE is any untoward medical occurrence, unintended  disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the 
medical device.   
Note 1: This definition includes events related to the medical device or the comparator. 
 
Note 2: This definition includes events related to the procedures involved. 
 Note 3: For users or other persons, this definition is restricted to events related to medical devices. 
 
Documented pre-existing conditions are not considered to be reportable AEs unless there is a change in the 
nature or severity of the condition 
OR 
A condition requiring a preplanned procedure unless the condition worsened since screening 
11.1.2 Serious Adverse Event (SAE) 
A serious adverse event (SAE) is any untoward medical occurrence in a subject that meets the criteria of 
“serious.”  A SAE is one that: 
xled to death, 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 40 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xled to serious deterioration in the health of the subject that either resulted in 
xa life-threatening illn ess or injury, or 
xa permanent impairment of a body structure or a body function, or 
xan in-patient or prolonged hospitalization, or 
xmedical or surgical intervention to prevent life threatening illness or  injury or permanent 
impairment to a body structure or a body function, or 
xled to fetal distress, fetal death, or a congenital abnormality or birth defect. 
 NOTE: Planned hospitalization for a pre-existing condition or a procedure required by the clinical 
investigation plan, without serious deteriorat ion in health, is not considered an SAE. 
11.1.3 Customer Complaint 
Any written, electronic, or verbal communication indicati ng a deficiency in the identity, quality, durability, 
reliability, safety, effectiveness, or  performance of any product after it is released for distribution. 
 
11.1.4 Device Deficiency 
A device deficiency is an inadequacy of a medical device related to its iden tity, quality, durability, 
reliability, safety, or performance.  This may include malfunctions, misuse or use error and inadequate 
labeling. 
11.1.5 Adverse Event Severity Classification 
Severity will be defined accord ing to the following criteria: 
 
Mild Awareness of event, but easily tolerated 
Moderate Discomfort enough to cause some interference with activities of daily living (ADL) 
Severe Incapacitating, with an inability to perform ADL 
 
An AE can be classified as severe and not deemed an SAE. Similarly, an SAE is not automatically severe in 
nature. 
11.1.6 Adverse Event Relationship Classification  
Causality assessments define the re lationship between the use of the medical device (including the 
medical-surgical procedure) and the occurrence of  each adverse event. During causality assessment 
activity, clinical judgment shall be used and the relevant documents, such as the Clinical Evaluation 
Report and the Risk Management Repo rt shall be consulted, as all the foreseeable serious adverse events 
and the potential risks are listed and assessed there.  The presence of confounding factors, such as 
concomitant medication/treatment, the natural history of the underlying disease, other concurrent illness 
or risk factors shall also be considered. 
 
Each AE will be classified according to five different levels of causalit y. The Sponsor and the Investigators 
will use the following definitions to assess the relati onship of the serious adverse event to the medical 
device or procedures: 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 41 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Relationship to study product administration will be determined as follows: 
xNot related : relationship to the device or procedures can be excluded when: 
othe event is not a known side effect of the pr oduct category the device belongs to or of 
similar devices and procedures; 
othe event has no temporal relationship with the use of the device or the procedures; 
othe serious event does not follow a known resp onse pattern to the medical device (if the 
response pattern is previously known) and is biologically implausible; 
othe discontinuation of medical device appl ication or the reduction of the level of 
activation/exposure - when clinically feasible – and reintroduction of its use (or increase 
of the level of activation/exposure), do not impact on the serious event; 
othe event involves a body-site or an organ not expected to be affected by the device or 
procedure; 
othe serious event can be attributed to another cause (e.g. an underlying or concurrent 
illness/ clinical condition, an effect of an other device, drug, treatment or other risk 
factors); 
othe event does not depend on a false result gi ven by the device used for diagnosis, when 
applicable; 
oharms to the subject are not clearly due to use error; 
oIn order to establish the non-relatedness, not all the criteria listed above might be met at 
the same time, depending on the type of device/procedures and the serious event. 
 
xUnlikely : the relationship with the use of the device seems not relevant and/or the event can be 
reasonably explained by another cause, bu t additional information may be obtained. 
 
xPossible :  the relationship with the use of the device  is weak but cannot be ruled out completely. 
Alternative causes are also possible (e.g. an under lying or concurrent illness/ clinical condition 
or/and an effect of another device, drug or  treatment). Cases were  relatedness cannot be 
assessed or no information has been obtained should also be classified as possible. 
 
xProbable :  the relationship with the use of the device seems relevant and/or the event cannot 
reasonably explained by another cause, bu t additional information may be obtained. 
 
xCausal relationship : the serious event is associated with the device or with procedures beyond 
reasonable doubt when: 
othe event is a known side effect of the prod uct category the device belongs to or of 
similar devices and procedures; 
othe event has a temporal relationship with  device use/application or procedures; 
othe event involves a body-site or organ that 
the device or procedures are applied to; 
the device or procedures have an effect on; 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 42 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  othe serious event follows a known response  pattern to the medical device (if the 
response pattern is previously known); 
othe discontinuation of medical device a pplication (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of 
activation/exposure), impact on the seri ous event (when clinically feasible); 
oother possible causes (e.g. an underlying or co ncurrent illness/ clinical condition or/and 
an effect of another device, drug or trea tment) have been adequately ruled out; 
oharm to the subject is due to error in use; 
othe event depends on a false result given by the device used for diagnosis, when 
applicable; 
oIn order to establish the relatedness, not all the criteria listed above might be met at the 
same time, depending on the type of de vice/procedures and the serious event. 
 
The Sponsor and the Investigators will distinguish between the AEs related to the device and those 
related to the procedures (any procedure specific to the clinical investigation) . An adverse event can be 
related both to procedures and the device. Complications of procedures are considered not related if the 
said procedures would have been app lied to the subjects also in the absence of  device use/application. 
 
In some particular cases the event may be not adequa tely assessed because information is insufficient or 
contradictory and/or the data cannot be verified or  supplemented. The Sponsor and the Investigators will 
make the maximum effort to define and categorize the event and avoid these situations. Where the 
Sponsor remains uncertain about cla ssifying the serious event, it shou ld not exclude the relatedness and 
classify the event as “possible”.  
 
11.1.7 Adverse Event Outcome Classification  
Outcome of the event will be defined according to the following: 
 
xFatal:  This event is determined to be the cause of death. 
 
xNot Recovered/Not Resolved:  The event has not fully resolved at the end of the study. 
 
xRecovered/Resolved: The event has fully resolved at the end of the study. 
 
xRecovered/Resolved with sequelae : The event has resolved, but retained pathological conditions 
resulting from the prio r disease or injury. 
 
xRecovering/Resolving: The event is ongoing at the end of the study. 
 
xUnknown 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 43 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  11.2. Recording of Adverse Events 
Assessment of the occurrence of an AE will be based on changes in the subject’s physical examination, 
laboratory results and/or signs and symptoms. The reco rding of AEs for all enrolled subjects will begin at 
the start of baseline imaging proced ures (MRE) and end  14 days after completion of the IC procedure. 
Subjects with AEs at  14 days afte r the IC procedure will be followed for 30 days or until event resolves, 
whichever comes first. Medica l care will be provided, as defined in  the informed consent, for any AE 
related to study participation. Adverse events will be  collected on an AE eCRF and applicable source 
documentation. To the extent possible, the event to be recorded and reported is the event diagnosis as 
opposed to event symptoms (e.g., fever, chills, naus ea and vomiting in the presence of a clinically 
diagnosed infection is to be reported as infection only). 
11.3. Reporting of Adverse Events 
Please refer to Table 3 for a list of the minimum AE reporting requirements for Investigators.  If local 
regulations or IRB/EC require faster  reporting, then the Investigator w ill adhere to those requirements.  
Reporting of all safety events to the Sponsor will be completed through Investigator submission of the AE 
eCRF in the remote data capture (RDC) system.  In ca se of emergency only for SAEs (ex. RDC system is 
unavailable), the Clinical Safety Specia list may be contacted directly at rs.mstsafetymitg@medtronic.com  ; 
this will not serve as a substitute for pr oper reporting on the appropriate eCRF.  
 
Table 3: Investigator AE Reporting Requirements 
 
Type  Report to  Reporting Timeframe (from time of learning of 
event)  
Adverse Event (AE) IRB/EC  Per IRB/EC reporting requirements 
Sponsor  Within 10 working days  
Serious Adverse Event (SAE)
 Sponsor  Within 24 hours  
IRB/EC  Per IRB/EC reporting requirements  
 
Device Deficiency Sponsor (technical support)
 Within 48 hours  
IRB/EC  If SAE occurs due to the device deficiency, within 24 
hours of learning of the event and per IRB/EC reporting requirements
 
Device Related AE/SAE
 Sponsor  Within 24 hours  
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 44 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Events will be reviewed by the Sp onsor to determine any reporting ob ligations to the FDA or National 
Competent Authorities as well as IR B/EC. Reporting will occur within th e timelines per local regulations 
and requirements. 
11.4. Notification to Authorities 
The following events are generally co nsidered reportable during the course of this study and should be 
reported to the Sponsor: 
 
xany SAE 
xany Device Deficiency that might have led to an SAE if  
osuitable action had not been taken or  
ointervention had not been made or  
oif circumstances had been less fortunate  
xnew findings/updates in relation to already reported events.  
xdeaths 
 
Events will be reviewed by the Sp onsor for reporting obligations to National Competent Authorities. 
Reporting to National Competent Authorities will occur within the timelin es described in the study Safety 
Plan by the Sponsor.  
11.5. Device Deficiencies 
 All device deficiencies will be documented on the appropriate Device malfunct ion eCRF and the device 
should be returned to the Sponsor for analysis, if po ssible. Instructions for returning the device will be 
provided.  Device deficiencies should also be  documented in the subject’s medical record. 
 Device deficiencies are NOT to be reported as AEs. Ho wever, if there is an AE that results from a device 
deficiency, that specific event would be recorded on the appropriate eCRF. 
 A device deficiency must be re ported to Medtronic (technical support) within 48 hours after the 
investigator is made aware of the event.  
 
12. Data Review Committees  
A Medical Advisor and Steering Committee will be utilized  in this study. This study will not have a Data 
Monitoring Committee (DMC) or an Advers e Events Advisory Committee (AEAC).  
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 45 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  12.1 Medical Advisor 
The Sponsor will utilize a Medical Advisor to provide an independent medical review according to the 
study safety plan. The Medical Advisor will not be affiliated with an  investigative center.  
 
12.2 Steering Committee 
The Steering Committee will consist of Investigators participating in this study, expert 
gastroenterologists, as well as appropriate members of  Medtronic Clinical and Medical Affairs. The role of 
the Steering Committee is to make recommendation s on the design and conduct of the study, the 
analysis of data, and the communication of result s in alignment with the Medtronic Publication and 
Authorship Policy. The Steering Committee will also review aggregate adverse event data on an as 
needed basis, as described in the Steering Committee Charter. 
 
13. Statistical Design and Methods 
13.1 Sample Size Determination 
The sample size for this study will be comprised of subjects enrolled by April 30, 2019 forming a 
convenient sample.  Therefore, the study is not powered to make statistical inference. 
13.2 Effectiveness Analyses 
Sensitivity, Specificity, PPV and NPV will be estima ted for each treatment group, along with the 95% 
confidence interval. The difference  between treatment groups in Se nsitivity and Specificity will be 
compared.     
13.3 Safety Analysis 
Individual listings of AEs, including type of device, AEs (reported term) start da te, duration, severity, and 
procedure-relatedness will be provide d. Procedure relatedness will be asse ssed separately relative to the 
imaging modality and colonoscopy, as described in Se ction 13.1.9. The recording of AEs for all enrolled 
subjects will begin with the start of baseline imaging procedures (MRE) and 2 weeks following the final 
imaging procedure, IC. Adverse events will be su mmarized using frequency counts and percentages. 
Descriptive statistics will be provided by treatment gr oup and by severity and relationship, according to 
the definitions in Section 13.1.9.   
13.4 Analysis Populations 
The effectiveness and safety analyses will be based on  all subjects who go through procedures MRE, CE, 
and IC modalities and can be evaluated for overall acti ve CDat baseline (i.e., a modified intent-to-treat 
(mITT) population).   
The effectiveness analyses will also be conducted on  the per protocol population, which includes all 
subjects in the mITT population who have no major prot ocol deviations (defined to be protocol violations 
that may have a significant impact on subject ou tcomes) and who do not meet any of the following 
criteria: 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 46 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xSubject withdraws 
xCapsules remained in the stomach or small bowel during the entire procedure 
xSystem technical failure 
 
Subgroup analyses will be performed on following de signated bowel segments: proximal small bowel, 
terminal ileum, and colon. Additional analyses may also  be explored and will be specified in the Statistical 
Analysis Plan (SAP). 
 
The SAP will include procedures for reporting any de viation(s) from the original statistical plan, 
specifications for subgroup analysis, and criteria for the termination on statistical grounds. Changes to 
the planned statistical analysis as defined in the protocol will be documented in the SAP.  
13.5 Interim Analyses 
No interim analysis is planned for this study.   
13.6 Handling of Missing Data 
All practical monitoring and follow-up steps will be take n to ensure complete and accurate data collection. 
No data imputation for missing data  will be performed for the primary an alysis.  As sensitivity analysis, 
missing data strategies such as multiple imputati ons may be used to assess the robustness of study 
results.   
14. Ethics 
14.1. Statement(s) of Compliance  
This clinical investigation will be conducted in accord ance with the protocol and ethical principles that 
have their origin in the Declaration of Helsinki (2 013 version). In Austria and Israel, local laws and 
regulations for the execution of a post-market, non-regu latory clinical trial will be followed. In the US, the 
study will be conducted in compliance with the abbrevia ted requirements for a non-significant risk IDE as 
defined in 21 CFR 812.2(b). All principles of the Decl aration of Helsinki have been implemented in this 
clinical study by means of the pati ent informed consent process, IRB/EC approval, clinical study training, 
clinical study registration, publication policy.  
 
The clinical investigation will not begin at a given site  until the required approvals/favorable opinions from 
the IRB/EC and/or notification/approv als from a regulatory authority ha ve been obtained, as appropriate 
and a Site Activation Letter has been provided by th e Sponsor. Should an IRB/EC or regulatory authority 
impose any additional requirements, they will be followed. PillCam® Crohn’s has been approved for use 
in the US (K170210), Israel and Europe.  
 
Information regarding the study and st udy data will be made available via publicatio n on clinicaltrials.gov 
([STUDY_ID_REMOVED]).  Additionally, the results of this stud y will be submitted for publication in an appropriate 
journal. 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 47 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  15. Study Administration 
15.1. Monitoring  
Monitoring will be conducted to ensure the protecti on and safety of human subjects, the quality and 
integrity of the clinical data, and compliance with the protocol. The Moni toring Plan will give details on 
how and when data review will be conducted by clinical monitors. It will be updated and revised as 
needed due to changes in documents or processes. 
 
Employees of the Sponsor, or its designees, who ha ve received appropriate training, will serve as the 
Study Monitor(s). Monitoring visits will be cond ucted based on Medtronic’s Standard Operating 
Procedures and the needs of the study. Quality document s will be followed for the conduct of all activities 
related to monitoring for this study. 
 Site Qualification and Initiation Visits will be comp leted at each site prior to enrollment of the first 
subject. On Site study monitoring activities will include an inspection of completed study documents, 
source document verification and re porting, verification of database  accuracy and completeness. All 
subjects enrolled in the study will be monitored and th e eCRF data verified against the subjects’ original 
source documents. Following each monitoring visit, a report will be prepared by the Monitor. From 
initiation of study to close out visit, the Study Moni tor(s) and Clinical Research Specialist(s) will share 
responsibility for communications between the Study Investigators and the Sponsor. 
 
Site visits will be conducted by an authorized Medt ronic representative to inspect study data, subjects’ 
medical records, and eCRFs in acco rdance with appropriate FDA regula tions (US only) and the respective 
local and national governme nt regulations and guidelines (if applicable). The Study Investigator and the 
investigating site will permit author ized clinical research personnel and clinical monitors from Medtronic 
and/or designee(s) employed by Medtronic to review co mpleted eCRFs, IRB/EC deci sions, and clinical site 
records, and facilities relevant to this study at regular intervals throughout the study per the monitoring 
plan. Additionally, subject charts and clinical records will be requested and reviewed so that protocol 
adherence and source documentation can be verified . In instances where data protection regulations 
prohibit the direct examination of hospital records by  the study Sponsor or designee(s), the Investigator 
will cooperate in a system of source data verification with the Sponsor.  Monitoring may be performed with 
in person visits or remotely, when applicable. 
 
All monitoring visits to the investigational center will be recorded using the Monitoring Visit Log. The log 
will be kept in the site regulatory binder and a co py will be collected and submitted to the Sponsor. 
 
To ensure the rights, safe ty, and welfare of study subjects are be ing maintained, the monitor will review 
training records to ensure all study staff are adequa tely trained on the study protocol and use of the 
study devices. If the monitor discovers that an Inves tigator is not complying with the signed Investigator 
Agreement, the investigational plan , applicable laws, or any conditio ns of approval imposed by the 
reviewing IRB/EC, the monitor will report to the Sp onsor and take such steps necessary to promptly 
secure compliance. If compliance cannot be secured, device shipments to the Investigator may be discontinued and the Investigator’s participation in the investigation terminated. The monitor shall also 
require such an Investigator to di spose of or return the device, unless this action would jeopardize the 
rights, safety, or welfare of a subject.  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 48 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  15.2. Data Management 
The Sponsor will oversee and/or perform all data ma nagement functions. Data  management functions 
include database development, system  maintenance, data queries, and report generation. This study will 
utilize Oracle to manage data via RDC. The RDC system  is a validated technology system, compliant with 
21 CFR Part 11, and adheres to all applicable federal regulations.  
 
15.2.1 Data Collection 
 All data required for analysis will be collected and entered on standard ized eCRFs using OC-RDC module.  
 
Required data will be recorded on eCRFs by authorized  site personnel as indica ted on the Delegation of 
Authority Log. The Investigator will ensure that all eCRFs are completed promptly, completely, and 
accurately. Information on case report forms must conform to the information in the source documents.  
 
Investigators must ensure that clinical records clea rly indicate that the subject has been enrolled in a 
clinical investigation. Regulations require that Inve stigators maintain informat ion in the study subject’s 
medical records to corroborate data collected on th e eCRF. In order to comply with these regulatory 
requirements, the study site will mana ge the following information, and retain/manage it as required to 
make it available to monitors, auditors and/or regula tory bodies. Complete hospital and clinical medical 
records for all study subjects should include all stud y required procedures, labs and assessments as noted 
in Study schedule and Site Collection Data.  
 
15.2.2 Data Access 
 Secure access to the RDC system w ill be maintained. Users will be give n appropriate levels of access for 
their delegated responsibilities in the study. An au dit trail is maintained in OC-RDC to capture any 
corrections or changes of the eCRFs.  If a person is only authorized to complete  CRFs or to make changes 
to an already signed CRF, the Investigator shall re-sig n this CRF. Training will be provided to users of the 
eCRF electronic data capture system. The RDC system  maintains an audit trail on entries, changes or 
corrections in the eCRFs. System backups for data st ored in the OC-RDC system will be consistent with 
Medtronic standard procedures.  
 
15.2.3  Electronic Case Report Form Guidelines 
 
Medtronic will provide detailed instructio ns to assist with eCRF completion.  
 
15.2.4 Data Queries 
 During monitoring visits, the Monitor will perform a source verification of required da ta points that comprise 
the eCRF for each subject. 
 Discrepancies will be queried by Medtronic and must be resolved by th e investigational site staff and PI in 
a timely manner, and as requested by Medtronic. 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 49 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Manual and/or automatic queries will be created in the OC-RDC system and will be issued to the site for 
appropriate response. The site staff will be responsible for responding to all queries in the database.  
xManual discrepancies will be issued in accordance with the Data Review Guidelines 
xAutomatic discrepancies will be issued in accordance with the Edit Check Document and the eCRF 
Database Question Specifications 
 
In the event of data discrepancies, investigational centers will be asked to  resolve queries electronically in 
the RDC system; otherwise, irresolvable data-related i ssues will be routed to the Sponsor for review and 
final disposition.   
Imaging discrepancies will be issued by the Imaging Co re Lab, ICON PLC, in SQUARE.  For information on 
accessing and responding to imaging queries,  please refer to the BLINK Imaging Manual. 
 
15.2.5 Audits and Inspections 
 
Medtronic-initiated audits or regulatory authority-in itiated inspections at the investigational sites may 
occur during the course of or after completion of the study.  In the event that an audit is initiated by 
Medtronic or a designee, the investigator shall allow access to the original medical records and provide all 
requested information.  In the even t that an inspection is initiate d by a regulatory authority, the 
investigator shall immediately notify Medtronic of th e impending inspection and allow the regulatory body 
access to the medical records and ot her information as required by applicable laws and regulations. 
 
15.2.6 Close Out  
 
Medtronic will only consider eCRFs to be complete when  all discrepancies have b een resolved by the site 
and reviewed and closed by Medtronic.  In addition, specific eCRFs must al so be reviewed and electronically 
signed by the Investigator, indicating his/her agreem ent with the accuracy of all recorded data. It is 
expected that the Investigator and his/her staff will cooperate with the monitori ng team and provide any 
missing data in a timely manner. 
 
15.3. Direct Access to Source Data/Documents  
The investigator(s)/institution(s)  will permit study-related monito ring, audits, IRB/EC review, and 
regulatory inspection(s) and provide direct access to source data/documents as per local policies and 
regulations.  
15.4. Confidentiality 
All records identifying the subject will be kept confidential and will not be made publicly available. 
 
Subject names will be kept confidential. Only the subject number will be recorded  in the eCRF , and if the 
subject name appears on any other document, it must  be obliterated. In cases where the local law does 
not allow using the su bject initials, for example in Europe, se rial number will be appointed (e.g. AAA, 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 50 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  BBB). Study findings stored on a computer will be stor ed in accordance with lo cal data protection laws. 
The subjects will be informed in writ ing that representatives of the Sponsor, IRB or Regulatory Authorities 
may inspect their medical records to verify the info rmation collected, and that all personal information 
made available for inspecti on will be handled in stri ctest confidence and in a ccordance with local data 
protection laws. 
 
Subjects will also be informed that information regarding the study that does not include subject identifiers will be posted on clinicaltrials.gov. 
 
If the results of the study are published, the subject’s identity will remain confidential. The Investigator will 
maintain a list to enable subjects’ records to be identified. 
15.5. Liability 
Given Imaging Ltd, is a wholly owned subsidiary of Medtronic, which as the parent company of such 
entity maintains appropriat e clinical study liability insurance coverage as required under applicable laws 
and regulations and will comply with applicable lo cal law and custom concerning specific insurance 
coverage. If required, a clinical study insurance st atement/certificate will be provided to the IRB/EC. 
15.6. CIP Amendments 
A CIP amendment will be prepared wh en there are revisions that are si gnificant changes or corrections, 
or modifications that impact subject safety, ethi cal conduct, data integr ity or study design. CIP 
amendments must undergo review by IRB/EC and any appropriate regulatory authority and will be logged 
in the document version history (Section 1). IRB/EC  approval, site training and a new Acknowledgement 
form will be signed and returned befo re any new procedures take place. 
15.7. Record Retention 
The Investigator and the Sponsor will maintain th e records of the study including all pertinent 
correspondence, the study protocol with any/all amen dments, all correspondence with and approval from 
the IRB/EC, the clinical study agre ement, the Investigator Agreement, device accountability records, 
individual subject records, and signed ICFs. In addi tion, the Investigator will retain the source documents 
from which the information entered on the eCRF wa s derived. Original source data that supports the 
eCRF entry must be maintained by the Investigator in  compliance with national regulations. Investigator 
records are subject to inspection and copyin g by regulatory authorities and Medtronic 
 
Subject files and other source data must be kept for a period of not less than 2 years after the latter of 
the following two dates: the date on which this investigation is terminat ed or completed, or the date that 
the records are no longer required for purposes of supporting a premarket application. Records may need 
to be maintained by the Investigator for a longer durati on if national regulations require or if agreed to in 
writing with Medtronic. The Investigator should not dispose of these records without the approval of the 
Sponsor. The Investigator should take measures to pr event accidental or early destruction of the clinical 
study related material. Should the Investigator wish to  assign the study records to another party or move 
them to another location, advance written notice should be given to the Sponsor. 
 
All data and documents should be made available if requeste d by relevant authorities. 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 51 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
   
15.8. Publication and Use of Information 
The Medtronic Publication and Authorship Policy is a ligned with the International Committee of Medical 
Journal Editors (ICMJE) recommendations (www.icmje.org). Medtronic will seek to publish, in appropriate 
peer-reviewed journals and scientific  conferences, results of clinical  studies where human subjects are 
involved, regardless of outcome. In formation regarding the study and st udy data will be made available 
via publication on clinicaltrials.gov. Additionally, the results of this study will be submitted for publication 
in an appropriate journal. While study results are owne d by Medtronic, all data on which a publication is 
based will be made available to all authors as required for their pa rticipation in the publication process. 
Furthermore, data may be published or used by study investigators provided that such publication or use 
is in accordance with this this protocol, the Medt ronic-MITG Publication and Authorship Policy, and the 
Clinical Investigation Agreement. Investigators must su bmit a copy of all manuscripts and/or abstracts to 
Medtronic for review and comment 30 days prior to planned submission. Medtronic acknowledges that its 
right to review and comment shall re late solely to the proprietary, lic ensing, and/or confidential rights 
Medtronic may have in such proposed publication, ra ther than whether such re sults and/or opinions are 
favorable to Medtronic.  
 
The publication of substudies, post-hoc analyses, regi onal results, or single-center experiences based on 
multicenter clinical studies should no t precede that of the primary multic enter publication, and should cite 
the primary publication whenever possible, as requ ired by specific journal and scientific meeting 
guidelines.  
 
Medtronic involvement in a publication (e.g., funding of the study; sponsor of the study; collection, 
analysis, and interpretation of data; professional writing assistance) must be disclosed according to 
journal-specific policies, submission requirements, and prevailing editorial standards, in addition to those 
specified by ICMJE. Authors must ensure that an acknowledgement/dis closure statement is included in 
the body of the manuscript for Medtronic to review fo r accuracy. All authors must also disclose financial 
or personal affiliations that could be considered conflicts of interest as per journal/conference 
requirements. 
 To enable health care providers, payers, and pati ents access to the wealth of Medtronic’s research, 
Medtronic will report its scientific data in accordance with the prin ciples outlined in the Guidance 
Document on Registration and Reporting Results of  Company-Sponsored Clinical Trials Under FDAAA 
2007 (Title VIII).   
15.9. Suspension or Early Termination 
Medtronic reserves the right to discontinue the study at any stage, with suitable written notice to all 
investigators, all reviewing IRB/EC s, FDA and Competent Authorities. The appropriate ethics committees 
will be notified of discontinuation of the study for any reason no later than 5 working days after the 
Sponsor makes this determination.  In addition, loca l ethics committee and/or regulatory authority can 
decide whether the study is to be te rminated and will notify the Sponsor. 
 
Similarly, investigators may withdraw from the study at  any time, subject to providing written notification 
to Medtronic 30 days prior to the date they intend to withdraw. However, Medt ronic and investigators will 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 52 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  be bound by their obligation to complete the follow-up of subjects already partic ipating in the study. The 
subjects must be followed accordin g to the clinical protocol, and in formation obtained during subject 
follow-up shall be reported to Medtronic on the appropriate eCRF. 
Suspension or termination of a site may include but is not limited to: 
xEthics Board approval expiration 
xConsistent non-compliance to the protocol (e.g. failure to follow subjects, etc.) 
xLack of enrollment 
xNon-compliance to regulations and the terms of the Agreement with Medtronic  
xEthics Board suspension of the site 
 
If the site terminates or su spends participation without prior agreement of Medtronic: 
xThe site must promptly inform Medtronic and provide a detailed written explanation of the termination 
or suspension 
xThe site must promptly inform the institution (where required per regulatory requirements) 
xThe site must promptly inform the Ethics Board, if applicable       
                                                       
If the Ethics Board terminates or suspends its approval:  
 
xThe site must promptly inform Medtronic and provide a detailed written explanation of the termination 
or suspension within 5 working days. 
xPatient enrollment must stop until the Ethics Board suspension is lifted 
xSubjects already enrolled should continue to be followed in accordance with the Ethics 
xBoard policy or its determination that an overriding safety concern or ethical issue is involved 
xThe site must inform his/her institution (where required per local requirements) 
xThe site must promptly inform the patients, if applicable 
 
16. References 
1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing 
incidence and prevalence of the inflammatory bowel diseases wit h time, based on systematic 
review. Gastroenterology. 2012;142(1):46-54 e42; quiz e30. doi:  10.1053/j.gastro.2011.10.001. 
PubMed PMID: 22001864.2. de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque  CG, Souza CL, et al. 
Inflammatory Bowel Disease: An Overview of Immune Mechanisms an d Biological Treatments. 
Mediators of inflammation. 2015;2015:493012. doi: 10.1155/2015/ 493012. PubMed PMID: 
26339135; PubMed Central PMCID: PMC4539174.
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 53 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  3. Kefalas CH. Gastroduodenal C rohn's disease. Proceedings. 2003 ;16(2):147-51. PubMed 
PMID: 16278730; PubMed Central PMCID: PMC1201000.4. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R , et al. Long-term 
evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8(4):244-50.
PubMed PMID: 12131607.5. Lee SM, Han EC, Ryoo SB, Oh HK, Choe EK, Moon SH, et al. Long -term Outcomes 
and Risk Factors for Reoperation After Surgical Treatment for G astrointestinal Crohn Disease 
According to Anti-tumor Necrosis Factor-alpha Antibody Use: 35 Years of Experience at a 
Single Institute in Korea. Annals of coloproctology. 2015;31(4) :144-52. doi: 
10.3393/ac.2015.31.4.144. PubMed PMID: 26361616; PubMed Central  PMCID: PMC4564666.
6. Ladas SD, Triantafyllou K, Spada C, Riccioni ME, Rey JF, Niv Y, et al. European 
Society of Gastrointestinal Endoscopy (ESGE): recommendations ( 2009) on clinical use of video 
capsule endoscopy to investigate small-bowel, esophageal and co lonic diseases. Endoscopy. 
2010;42(3):220-7. doi: 10.1055/s-0029-1243968. PubMed PMID: 201 95992.
7. Kopylov U, Seidman EG. Clinical applications of small bowel c apsule endoscopy. 
Clinical and experimental gastroenterology. 2013;6:129-37. doi:  10.2147/CEG.S48005. PubMed 
PMID: 23983481; PubMed Central PMCID: PMC3751460.8. Eliakim R, Yassin K, Niv Y, Metzger Y, Lachter J, Gal E, et a l. Prospective multicenter 
performance evaluation of the second-generation colon capsule c ompared with colonoscopy. 
Endoscopy. 2009;41(12):1026-31. doi: 10.1055/s-0029-1215360. Pu bMed PMID: 19967618.
9. Spada C, Hassan C, Munoz-Navas M, Neuhaus H, Deviere J, Focke ns P, et al. Second-
generation colon capsule endoscopy compared with colonoscopy. G astrointest Endosc. 
2011;74(3):581-9 e1. doi: 10.1016/j.gie.2011.03.1125. PubMed PM ID: 21601200.
10. Rex DK, Adler SN, Aisenbe rg J, Burch WC, Jr., Carretero C, C howers Y, et al. Accuracy 
of capsule colonoscopy in detecting colorectal polyps in a scre ening population. 
Gastroenterology. 2015;148(5):948-57 e2. doi: 10.1053/j.gastro. 2015.01.025. PubMed PMID: 
25620668.11. Leighton JA, Helper DJ, Gralnek IM, Dotan I, Fernandez-Urien  I, Lahat A, et al. 
Comparing diagnostic yield of a novel pan-enteric video capsule  endoscope with 
ileocolonoscopy in patients with active Crohn's disease: a feas ibility study. Gastrointest Endosc. 
2016. doi: 10.1016/j.gie.2016.09.009. PubMed PMID: 27658907.12. Mitselos IV, Christodoulou DK, Katsanos KH, Tsianos EV. Role  of wireless capsule 
endoscopy in the follow-up of inflammatory bowel disease. World  J Gastrointest Endosc. 
2015;7(6):643-51. doi: 10.4253/wjge.v7.i6.643. PubMed PMID: 260 78832; PubMed Central 
PMCID: PMC4461938.
13. Efthymiou A, Viazis N, Mantzaris G, Papadimitriou N, Tzourma kliotis D, Raptis S, et al. 
Does clinical response correlate with mucosal healing in patien ts with Crohn's disease of the 
small bowel? A prospective, case-series study using wireless ca psule endoscopy. Inflamm Bowel 
Dis. 2008;14(11):1542-7. doi: 10.1002/ibd.20509. PubMed PMID: 1 8521929.
14. Hall BJ, Holleran GE, Smith SM, Mahmud N, McNamara DA. A pro spective 12-week 
mucosal healing assessment of small bowel Crohn's disease as de tected by capsule endoscopy. 
Eur J Gastroenterol Hepatol. 2014;26(11):1253-9. doi: 10.1097/M EG.0000000000000194. 
PubMed PMID: 25264865.
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 54 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  15. Niv E, Fishman S, Kachman H, A rnon R, Dotan I. Sequential ca psule endoscopy of the 
small bowel for follow-up of patients with known Crohn's diseas e. Journal of Crohn's & colitis. 
2014;8(12):1616-23. doi: 10.1016/j.crohns.2014.03.003. PubMed P MID: 24666976.
16. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Ko rnbluth A, Diamond R, et 
al. Clinical disease activity , C-reactive protein normalisation  and mucosal healing in Crohn's 
disease in the SONIC trial. Gut. 2014;63(1):88-95. doi: 10.1136 /gutjnl-2013-304984. PubMed 
PMID: 23974954.17. Boal Carvalho P, Rosa B, Dias de Castro F, Moreira MJ, Cotte r J. PillCam COLON 2 in 
Crohn's disease: A new concept of pan-enteric mucosal healing a ssessment. World J 
Gastroenterol. 2015;21(23):7233-41. doi: 10.3748/wjg.v21.i23.72 33. PubMed PMID: 26109810; 
PubMed Central PMCID: PMC4476885.
18. Dave M, Loftus EV, Jr. Mucosal healing in inflammatory bowel  disease-a true paradigm 
of success? Gastroenterology & hepatology. 2012;8(1):29-38. Pub Med PMID: 22347830; 
PubMed Central PMCID: PMC3277196.19. Orlando A, Guglielmi FW, Cot tone M, Orlando E, Romano C, Sin agra E. Clinical 
implications of mucosal healing in the management of patients w ith inflammatory bowel disease. 
Dig Liver Dis. 2013;45(12):986-91. doi: 10.1016/j.dld.2013.07.0 05. PubMed PMID: 23993738.
20. D'Inca R, Caccaro R. Measuring disease activity in Crohn's d isease: what is currently 
available to the clinician. Clinical and experimental gastroent erology. 2014;7:151-61. doi: 
10.2147/CEG.S41413. PubMed PMID: 24876789; PubMed Central PMCID:  PMC4035027.
21. Flamant M, Trang C, Maillard O, Sacher-Huvelin S, Le Rhun M,  Galmiche JP, et al. The 
prevalence and outcome of jejunal lesions visualized by small b owel capsule endoscopy in 
Crohn's disease. Inflamm Bowel Dis. 2013;19(7):1390-6. doi: 10. 1097/MIB.0b013e31828133c1. 
PubMed PMID: 23552764.
22. Papay P, Ignjatovic A, Karmir is K, Amarante H, Milheller P, Feagan B, et al. Optimising 
monitoring in the management of Crohn's disease: a physician's perspective. Journal of Crohn's 
& colitis. 2013;7(8):653-69. doi: 10.1016/j.crohns.2013.02.005.  PubMed PMID: 23562672.
23. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelma n W, Bryant RV, et al. 
Selecting Therapeutic Targets in Inflammatory Bowel Disease (ST RIDE): Determining 
Therapeutic Goals for Treat-t o-Target. Am J Gastroenterol. 2015 ;110(9):1324-38. doi: 
10.1038/ajg.2015.233. PubMed PMID: 26303131.24. Rozendorn N, Klang E, Lahat A, Yablecovitch D, Kopylov U, El iakim A, et al. 
Prediction of patency capsule retention in known Crohn's diseas e patients by using magnetic 
resonance imaging. Gastrointest Endosc. 2016;83(1):182-7. doi: 10.1016/j.gie.2015.05.048.
PubMed PMID: 26142554.
25. Signorelli C, Rondonotti E, Villa F, Abbiati C,  Beccari G, Avesani EC, et al. Use of the Given 
Patency System for the screening of patients at high risk for capsule retention. Dig Liver Dis. 
2006;38(5):326-30. doi: 10.1016/j.dld.2006.01.010. PubMed PMID: 16527556. 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 55 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17. Appendices  
17.1 Appendix A – Mont real Classification 
17.2 Appendix B - Study Schedule for C linical Laboratory and Pregnancy Tests 
17.3 Appendix C - MRE Procedure Instructions 17.4 Appendix D – P illCam® Patency Study 
17.5 Appendix E – CE Procedure Instructions 
 17.5.1 Appendix E1 – CE Bowel Preparation Instructions 
 17.5.2 Appendix E2 – CE Subject Instructions Form  17.5.3 Appendix E3 – CE Procedure Instructions  17.5.4 Appendix E4 – CE Bowel Cleansing Scale 17.6 Appendix F – Ileocolonosc opy Procedure Instructions 
 17.6.1 Appendix F1 - Ileocolonoscopy Bowel Preparation  17.6.2 Appendix F2 - Ileocolonoscopy Subject Instructions Form 
 17.6.3 Appendix F3 - Ileocolonoscopy Bowel Cleansing Scale 
17.7 Appendix G – Accuracy for Ac tive Crohn’s Disease in Overall and Designated Bowel Segments 
17.8 Appendix H – Scores for Capsule endoscopy, Ileocolonoscopy, and MRE 
 17.8.1 Appendix H1 – Lewis Score 17.8.2 Appendix H2 – Simple Endoscopic Score for Crohn’s Disease Index (SES-CD) Score  17.8.3 Appendix H3 - Magnetic Resonance Index of Activity (MaRIA) Score 17.9 Appendix I – Patient Satisfaction Questionnaire 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 56 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.1 Appendix A – Mont real Classification 
Data for Montreal cla ssification will be captured at screening.  
 
Montreal classification: 
 
i. Age at diagnosis (years) 
a. < 16, A1 
b. 16-40, A2 
c. > 40, A3 
ii.  Disease behavior 
a. Inflammatory, B1 b. Stricturing, B2 
c. Penetrating, B3 
iii.  Disease location 
a. Ileum, L1 
b. Colon, L2 c. Ileocolon, L3 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 57 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.2 Appendix B - Study Schedule for Clinical Laboratory and 
Pregnancy Tests 
 
1. Stool Clostridium difficile  (if not done within previous 3 months). 
2.  Stool ova/parasites OR stool PCR microorganism  panel (if not done within previous 3 months). 
3. Clinical Chemistry  
 Blood urea nitrogen (BUN) 
 Serum creatinine 
 Serum albumin   Fecal calprotectin 
 C-reactive protein (CRP) 
4. Complete blood count (CBC): 
 Hemoglobin 
 Hematocrit  Erythrocyte count (RBC) 
 Leukocytes (WBC) 
 Absolute Neutrophils 
 Platelets  
5. Pregnancy Test - Female subjec ts will be assessed for childbearing potential, and if they do have 
childbearing potential, they will under go a pregnancy blood or urine test. If the test is positive, they will 
be withdrawn from the study. If the pregnancy te st is negative, these subjects should practice 
contraceptive methods through the course of the study. s.  
 
 Screening 
(No more 
than 30 
days prior to 
first Baseline 
Procedure - 
MRE) Baseline 
Procedure 
(Day 0)5     
Stool Clostridium 
difficile1 X      
Stool 
ova/parasites OR 
stool PCR 
microorganism panel
1 X      
BUN2 X      
Serum 
creatinine2,3 X      
Serum albumin   X     
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 58 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Fecal calprotectin4  X     
CRP  X     
CBC w differential  X     
Pregnancy test  X      
1. Prior standard of care C.difficile and stool O&P /PCR microorganism panel results may be leveraged for the screening visit 
once informed consent has been collected and provided that the da te of results is no more than 3 months prior to informed 
consent date.   These lab results, along with pregnancy test, must be evaluated as pa rt of inclusion/exclusion criteria prior to 
subject enrollment.    
2. BUN and serum creatinine data will be collected to evaluate  renal function and results must be evaluated prior to MRE .          
3. Serum creatinine measurement will be used to estimate the glomer ular filtration rate (eGFR) and results must be evaluated 
prior to MRE.                                              
4. A central laboratory will be used for analysis of fec al calprotectin.  Please see Laboratory Manual for additional information. 
5. Baseline labs may be collected on the day of the MRE procedure, prior to the procedure.  
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 59 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.3 Appendix C - MRE Procedure Instructions 
The MRE procedure will be in accordance with Coimbra et al., Aliment Pharmacol Ther 2016; 43: 61–72.  
Instructions for subjects can be found in Appendix C1. 
All deviations from prep and procedural requirements  should be appropriately documented and reported. 
1. Subjects will fast for 4 hours and drink up to 1000-1800 mL of an oral non-absorbable bowel 
preparation solution (Breeza® [Beekley Medical, Bristol, CT, USA], or VoLumen® [Bracco 
Diagnostics Inc., Princeton, NJ, USA] or 5% mann itol solution). Non-proprietary oral contrasts 
containing sugar alcohols (e.g., 3% sorbitol soluti on) are also permissible,  but should be cleared 
with Medtronic prior to study initiation. 
2. An intravenous (IV) catheter will be placed into a peripheral vein.  
3. An IV or subcutaneous injection of an anti-perista ltic agent (0.5 mg glucagon [Lilly, Indianapolis, 
IN, USA] in the US or 10 mg buscopan [Boehringe r Ingelheim, Sant Cugat, Spain] in Europe) will 
be administered prior to scanning.  The anti-peris taltic agent can be administered in a split dose 
(prior to scanning and immediately prior gadolinium administration) or as a single dose prior to 
administration of gadolinium (step 5 below). 
4. Following a fast scout series and a succession of breath holds, T2-weighted true fast imaging 
with steady-state free precession (FISP) and T2-weighted single-shot fast spin echo (SSFSE) 
series will be acquired, with and without fat suppression, using coronal and axial images, as 
described in Table 2 of the BLINK Imaging Manual. The field of view will be adjusted to cover the 
digestive tract from the fundus of the stomach to the anus. It is appropriate to move the field of 
view inferiorly to not image the liver dome and stomach so that the anus is within the imaged 
volume.  The number of slices for each series will be adjusted to keep the series duration within 
approximately 25 seconds and to allow for accept able breath hold periods. Multiple staggered 
series will be allowed to fulfil the prescribed co verage.  Prone positioning is preferred by not 
mandatory.  Supine positioning is preferred for patients with end ileostomies. 
 
*Optional – it is optional for sites to acquire axial im ages using either types of pre-contrast pulse 
sequence instead of coronal images.  At least on e precontrast series should be acquired in the 
axial plane. 
5. A fast breath-hold 3D gradient-recalled echo (GRE) coronal T1-weighte d, fat-suppressed series 
will be acquired prior to and approximately 45 seconds and 180 seconds following the IV 
administration of an extracellular gadoliniu m-based contrast agent (such as 0.1 mmol/kg 
MultiHance [Bracco Diagnostics Inc., Princeton, NJ, USA], 0.1 mmol/kg Omniscan [GE Healthcare 
Inc., Oslo, Norway] or 0.1 mmol/kg Dotarem [Gue rbet LLC., Bloomington, IN, USA]). The small 
bowel (including duodenum), colon, rectum, and anus need to be imaged.  Required and 
suggested parameters are listed in Table 2 of th e BLINK Imaging Manual*.  Slice thicknesses can 
be interpolated. 
* Optional - For large patients, the coronal slice thickness can be increased to 4 mm and the axial 
slice thickness can be increased to 5 mm to pe rmit for coverage and appropriate signal, if 
needed. 
6. Finally, one final breath-hold series of axia l T1-weighted GRE with fat suppression will be 
acquired. 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 60 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.3.1 Appendix C1 - MRE Subject Instructions 
See attached document “Appendix C1_BLINK_MRE Subject Instructions” 
 
  
Subject Code: Page 1 of 3Subject Instructions
MRE Procedure
BLINK Clinical Trial (COVSBCC0549)
Thank you for your participation in this study. The preparation for your examination is a very 
important part of your exam. Please follow all instructions carefully to ensure a successful 
procedure.
• After completion of each step, check box ( 9) and specify time in the column on the right,        
otherwise detail why step was not followed in Comments section.
• Both you and the Research Staff Mem ber should sign and date Page 3 of this form
On the day of the examination :
• Bring these instructions with you to the clinic
• Dress in comfortable 2-piece clothingTo be completed by research staff:
Subject #:                                                     Site #:
Please arrive at the clinic on _____________ at __________ for your 
procedure.
Your MRE is scheduled to begin at ____________Contact for questions:Name: ___________________   Phone: ________________Date
TimeTime
COVSBCC0549 MRE Subject Instructions v3
Subject Code:Page 2 of 3Time Action "
The Day of the Examination
Day of the week:__________, Date:____/____/___
Start: 4 hours 
prior to procedure(see top of Page 1)
• Drink water only . No solid foods or other beverages.
As defined by 
Radiologist• Ingest 1000-1800mL of the bowel preparation solution provided to 
you.Start Time:
Finish Time:
As Scheduled • MRE Procedure
COVSBCC0549 MRE Subject Instructions  v3Subject #:
Subject Code:Page 3 of 3Time CommentsAdditional Information and Comments
COVSBCC0549 MRE Subject Instructions v3Subject #:
Research Staff Signature
Patient SignatureDate
Date
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 61 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.4 Appendix D – PillCam® Patency Study 
In all subjects with evidence of stricture on MRE, or according to investigator’s discretion, a PillCam® 
patency study must be performed prior to the PillCam® procedure. 
 
During the PillCam® patency study, if the patency ca psule is excreted structurally whole or located 
structurally whole in the colon at any time, then this confirms patency of the GI tract of the subject for 
objects the size of the capsule. The capsule is designed to dissolve starting 30 hours following ingestion, 
during a period of approximately 12 hours. If any time before 30 hours after capsule ingestion the 
patency capsule cannot be detected in the subject's body, it indicates the following: 
 
xThe PillCam® patency capsule was excret ed naturally and structurally whole 
xPatency of the GI tract for objects the size of the capsule is confirmed  
 
The PillCam® patency scanner is used to detect the presence of the patency capsule in the subject’s 
body. If desired, fluoroscopy or X-ray may be used.  The subject should return to  the clinic as close to, 
but no more than, 30 hours after ingestion of the pa tency capsule to be evalua ted – suggest scheduling 
subject appointment for 28 hours after initial ingestion.  
If the PillCam® patency scanner or x-ray does not de tect the patency capsule in the GI tract any time 
prior to 30 hours post-ingestion, this implies that it has been excreted structurally whole, and patency of 
the GI tract can be confirmed.  
 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 62 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.5 Appendix E – CE and IC Procedure Instructions 
This appendix includes instructions for the capsul e endoscopy (CE) and IC procedures in 4 parts: 
 
xAppendix E1 – CE Capsule and IC Bowel Preparation Instructions 
xAppendix E2 – CE Capsule and IC Subject Instructions Form 
xAppendix E3 – CE Procedure Instructions 
xAppendix E4 – CE and IC Bowel Cleansing Scale 
 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 63 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.5.1 Appendix E1 – CE and IC Bowel Preparation Instructions 
Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during 
the CE procedure day. All colon preparation products will be standard colon clea nsing products approved 
by the FDA and/or EMA.    Additional bowel prep af ter capsule endoscopy, prior to ileocolonoscopy is at 
the discretion of the investigator. 
 
Subjects will keep a timed diary of key preparation st eps and bowel activity, incl uding capsule excretion, 
located in Appendix E2.  CE Procedure Inst ructions can be located in Appendix E3.  
 
Preparation Procedure  
The Day Before the Procedure Day 
All Day Clear liquid diet. 
15 hours prior to capsule ingestion Begin ingestion of 2L PEG  (such as ELS; NuLYTELY, Braintree 
Laboratories, Braintree, MA), one 8-10 oz. cup every 10-15 minutes. 
13 hours prior to capsule ingestion Complete ingestion of 2L PEG 
Procedure Day 
3 hours prior to capsule ingestion  Begin ingestion of remaining 2L PEG, one 8-10 oz. cup every 10-15 
minutes. 
1 hour (±15 minutes) prior to 
capsule ingestion  Complete ingestion of remaining 2L PEG1,2. Subject should remain NPO 
until capsule ingestion.   Strongly suggest requiring subject to finish 
morning PEG in clinic to assure capsule ingestion occurs w ithin 1 hour 
(±15 minutes) of completion. 
As scheduled  Capsule Ingestion with a sip of water then resume NPO until Alert 1.  
Capsule MUST be ingested within 1 hour (±15 minutes) after completing 
ingestion of PEG. 
Alert 0 (1 hour after capsule 
ingestion) 10 mg Metoclopramide or 250mg oral Erythromycin 
Please note, not all subjects will receive Alert 0 
Alert 1 ( Upon SB Detection) 3 oz. (half bottle) SUPREP® (US), Eziclen®/Izinova® (EU) diluted per 
package insert instructions + drink 1L water 
Alert 2 ( 3 hrs later) 3 oz. (half bottle) SUPREP® (US), Eziclen®/Izinova® (EU) diluted per 
package insert instructions + drink 1L water 
Alert 3 (2 hrs later) 10 mg Bisacodyl suppository. 
1 Any subject ingesting <2.5L of PEG (combined between ev ening and morning dose) should not proceed with CE 
procedure and should be discontinued from the trial. 
2 Any subject requiring >3 hours to ingest the morning PE G dosage (2L) should not proceed with CE procedure and 
should be exited from the trial. 
 
Following capsule endoscopy procedure, physician must instruct subject regarding clear liquid diet and/or 
NPO status until completion of IC procedure.  Physician may administer additional prep following 
completion of the CE procedure, prior to the IC procedure at his/her discretion.  
 
EXAMPLE Subject Schedule fo r 8am capsule ingestion: 
The Day Before the Procedure Day 
All Day Clear liquid diet. 
5pm (15 hrs prior to scheduled 
ingestion) ) Begin ingestion of 2L PEG  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 64 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  7pm (13 hrs prior to scheduled 
ingestion) Complete ingestion of 2L PEG  
Procedure Day 
5am (3 hrs prior to scheduled 
capsule ingestion) Begin ingestion of remaining 2L PEG  
7am (±15 minutes) (1 hour prior to 
scheduled capsule ingestion) Complete ingestion of remaining 2L PEG. Subject should remain NPO 
until capsule ingestion. 
8am (08:00) Capsule Ingestion with a sip of water then resume NPO until Alert 1. 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 65 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.5.2 Appendix E2 – CE and IC  Subject Instructions Form 
During the CE procedure, subjects will be asked to use a Subject Instructions Form to document their 
activities during the bowel preparation and capsule ex amination. This form will be used to document the 
subject’s adherence to the procedure steps. The Subject Instructions Form will also serve as source data 
for eCRF entries. Site staff must complete the instruct ed “start” and “finish” time s in the left-hand column 
of the CE Subject Instruction Form to inform the pati ent when they should start and finish each step of 
the bowel prep, based on the timelines set in Ap pendix E1, CE Bowel Preparation Instructions. 
 
See attached document, “BLINK_CE an d IC Subject Instructions Form” 
 
  
Subject Code: Page 1 of 4Thank you for your participation in this study. The preparat ion for your examinations are very important part of 
your exam. Please follow all instructions carefully to ensu re adequate cleansing of the bowel for your 
procedure. The Research Staff will complete  the information in the left hand column, to indicate when you 
should start and finish each step of the procedures.  You must complete the column on the right, indicating the 
exact time you started and finished each step.  BOTH the Research Staff and Patient must sign and date Page 4.
•Important: After the capsule endoscopy, you must follow your physician’s instructions on what you can eat or 
drink until your ileocolono scopy procedure (IC) is complete; ei ther directly following the PillCam®Crohn’s 
procedure or the next morning.
• After completion of each step, check box ( 9) and specify time in the column on the right, otherwise detail 
deviation in comments
• During the preparation period do not take any iron supplements or vitamin supplements containing iron
• If you take anti-coagulants ( Warfarin, Aspirin) or antibiotics as a preventive treatment for heart disease, please 
consult your physician first
• It is recommended to use moist baby wipes instead of toilet paper
On the day of the Caps ule Endoscopy procedure :
• Bring these instructions and the remaining 2L of PEG (SF-ELS) with you to the clinic
• Dress in comfortable 2-piece clothing and bring any readi ng material or electronic personal entertainment you 
with to use during the capsule endoscopy procedure.
During your capsule endoscopy procedure:
•Try to remain active and take short walks, this c an speed up the transit of the capsule through your body. No 
sleeping.  
•Do not lean on or sit in metal chairs during the procedure as this can cause interference.
•Avoid intense sunlight during procedure
COVSBCC0549 PillCam Crohn’s and IC Subject Instructions v4To be completed by research staff:
Subject #:                                                    S ite #:
Please arrive at the clinic on:
____________ at __________ for your capsule endoscopy procedure  AND
____________ at __________ for your ileocolonoscopy procedure.
Contact for questions:
Name: __________________________  Phone: ___________________
Research Staff: Please complete the blank information in the left hand column o f Pages 2 and 3 to 
indicate when the subject should start and finish each step of the procedure based on the 
requirements in Appendix E1.  Remember to sign and date Page 4,  along with the patient.TimeTime DateSubject Instructions
Capsule Endoscopy (PillCam® Crohn’s) and Ileocolonoscopy 
Procedure
BLINK Clinical Trial (COVSBCC0549)
Date
Subject Code:Page 2 of 4Action "
The Day Before the Procedure
Day of the week:__________, Date:____/____/___
All day• Drink clear fluids only , see description below,  No solid foods.
• It is recommended to drink a lot of sugared clear drink of your 
choice through the day (e.g. carbonated soda, apple juice, energy  drinks etc.)
Afternoon• Prepare PEG solution according to the instructions on the package. 
Shake well until all the powder is dissolved and keep refrigerated
To be 
completed by Study Coordinator:
Expected 
Start:
____________
Expected 
Finish: 
____________
_•Document the time you actually Start and Finish each step in the 
column to the right 
• Drink ½ gallon (2 liters) of PEG (SF-ELS) solution, one
200-250ml cup every 10-15 minutes, for up to 2 hrs .  Do not ingest 
too quickly in order to avoid stomach discomfort. During this time, you should avoid drinking other fluids.
• Document the Start and End times of drinking the solution• Keep the remaining volume (1/2 gallon) of the PEG (SF-ELS) 
solution refrigerated and bring it with you on the day of the examination
• Contact the study coordinator in case you are having trouble 
completing the entire volume
Clear Liquid Diet
COVSBCC0549 PillCam Crohn’s and IC Subject Instructions  v4Subject #:
Actual Start:
Actual Finish:
Total PEG 
intake:
liters
•W a t e r• Apple, white cranberry, white grape juices• Tea or black coffee (no milk or cream)• Clear sports drinks or carbonated soft drinks (no red or purpl e colored)
• Popsicles or jello (any color except red or purple)• Bubble gum or hard candy (lemon or mint flavored) AVOID: Juices with pulp, milk, cream, soup or broth, alcoholic beverages and solid foods
Subject Code: Page 3 of 4Day of the Examination
(Day of the week:_________, Date:____/____/____)
Action "
All Day •Only clear fluids are allowed. No solid foods
To be completed 
by Study Coordinator:
Expected Start:
_____________Expected Finish: _____________• May start morning PEG at home depending on scheduled 
capsule ingestion time (see top of Page 1 for scheduled time)•Drink ½ gallon (2 liters) of PEG (SF-ELS) solution,
one 200-250ml cup every 10-15 minutes, for up to 2 hours.
•It is recommended that you bring a small amount of remaining 
PEG with you to the clinic to finish at the clinic. This will help ensure you ingest the PillCam capsule within  1hr of completing 
your PEG ingestion
• Try to avoid consumption of any other liquid during PEG ingestion• When finished, maintain a complete fast until instructed 
otherwise by the study staff. Actual Start:
Actual Finish:Total PEG intake:
liters
1 hour (
t15min) 
after finishing 
PEG•Ingest PillCam®Crohn’s capsule with a cup of water
ActionAlert Number 
& Time
Prokinetics10mg Metoclopromide or 250mg Erythromycin
*Not all patients will receive Alert 0 0________________
1stBoost•Drink SuPrep solution (0.5 bottle (88ml)  diluted to
240ml) 
•Drink at least 1 liter (Four 8 oz cups) of water 1________________
2ndBoost*
(3 hrs after 1st Boost)•Drink SuPrep solution (0.5 bottle (88ml)  diluted to
240ml) 
•Drink at least 1 liter (Four 8 oz cups) of water 2* ______________
Suppository
(2 hrs after 2nd Boost)Insert suppository (10mg Bisacodyl ) as described in the 
package insert 3________________
End of 
Procedure* Capsule was naturally excreted                   -- or --
Recorder (DR3) alert “End of Procedure”                     End of Procedure
________________
COVSBCC0549 PillCam Crohn’s and IC Subject Instructions v4*Subjects are allowed to leave the clinic (at the physician’s discretion) after Alert 2 is received and all associated actions 
completed, if the capsule is not yet excreted. If subject leaves before excretion they must insert the suppository when Alert 3 is received and document the time.  They must also document the time the capsule is excreted or “End of Procedure” alert is received.  They may disconnect the recorder at excretion or battery failure (whichever comes first). Subject #:
Subject Code:Page 4 of 4•Research Staff SignatureTime CommentsAdditional Information and Comments
COVSBCC0549 PillCam Crohn’s and IC Subject Instructions v4Subject #:
Research Staff Signature
Patient SignatureDate
Date
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 66 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.5.3 Appendix E3 – CE Procedure Instructions 
On the day of the examination, the arrival time of the subject at the clinic will be documented on the 
Subject Instructions Form (see Appendix E2) and the subject will complete the bowel preparation 
procedure as detailed in Appendix E1.  All deviatio ns from bowel prep and procedural requirements 
should be appropriately documented and reported.  
The subject’s last bowel movement should be clear to  yellow effluent prior to the CE exam.  Any subject 
ingesting <2.5L of PEG should not pr oceed with CE procedure and should be discontinued from the trial. 
 
After the final PEG ingestion, subjec ts should remain NPO until capsule ingestion.  Within 1 hour (±15 
minutes) of the final PEG ingestion,  the subject will swallow the PillCam® Crohn’s capsule with a cup of 
water.  The subject will then resume  their NPO status until they receive an alert. The subject will follow 
the instructions for any alert they receive until the capsule is excreted. The subject will be instructed to 
notify the staff upon exit of the capsule from the body and to record the time on the subject instruction 
form.  After the baseline capsule endoscopy procedure,  the subject should be instructed to follow the 
anesthesiologist’s instruction in regard to NPO status  until the completion of the baseline IC procedure. 
 
Throughout the CE procedure, the subject will be inst ructed to verify when the capsule has exited the 
body and to inform the physician or the clinical coordina tor of the time of exit. The time of exit should be 
documented on the Subject Instructions Form and in the eCRF.  
 
Throughout the CE procedure, the subjects will be inst ructed to notify the study physician if experiencing 
abdominal pain, headache, vomiting, bloating, and nausea which are anticipated symptoms that could be 
related to the procedure.   
The system may be disconnected upon one of the following: capsule excretion (“End of Procedure” alert) 
or until battery failure, whichever comes first. The PillCam® Recorder may also be removed in case of 
procedure failure. 
 Subjects will be allowed to leave th e clinic once the capsule is excret ed (“end of procedure” alert) OR 
once Alert 2 has been received and all associated in struction for Alert 2 is completed by the subject, 
approximately 8 hours after ingestion.  Subjects leavin g before excretion must be instructed and agree to 
the following; the importance of complying wi th these instructions should be stressed: 
 
xInsert the biscodyl suppository at home upon notification of Alert 3
xDocument the time of Alert 3 on the CE  Subject Instructions (Appendix E2).  
xEvaluate bowel movements for capsule excretion and document the time of excretion on the CE 
Subject Instructions (Appendix E2).  If the capsule is not excreted prior to returning to the clinic, 
the “End of Procedure” alert time or the time the battery failed should be recorded on the 
Subject Instructions, whichever occurs first.
xThe subject may disconnect the recorder at excretio n (“End of Procedure” alert) or battery failure 
(whichever comes first) and return the equipment to the clinic the next day.
 
  
 
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 67 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  Site staff must continue to follow the subject unti l the capsule is excreted.  If the capsule is not 
confirmed to have been excreted by 14 days after ingestion, then a plain abdominal film will be 
performed to verify the capsule exit. 
 
Since the capsule endoscopy and ileocolonoscopy share a single bowel prep, the physician may 
administer additional bowel prep at his/her discretion  if the ileocolonoscopy is to be conducted the day 
after completion of the capsule endoscopy.  The physician must also instruct the subject whether they may have a meal or must maintain clear liquid diet or NPO between the 2 procedures.  If the capsule has 
not been excreted by the time the IC is conducte d, and the battery has already failed, the colonoscopist 
may remove the capsule during IC. 
 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 68 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.5.4 Appendix E4 – CE an d IC Bowel Cleansing Scale 
 
 Cleansing Level Scale for Capsule Endoscopy  
Rating  Description  
Poor Inadequate  
Large amount of fecal residue precludes a complete examination  
Fair Inadequate, but examination completed  
Enough feces or turbid fluid to prevent a reliable examination  
Good Adequate  
Small amount of feces or turbid fluid not interfering with examination  
Excellent  Adequate  
No more than small bits of adherent feces 
Adapted from Leighton JA et al. Endoscopy 2011;43:123 -7. 
 
   
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 69 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.7 Appendix F – Accuracy for Active Crohn’s Disease in Overall 
and Designated Bowel Segments 
 
Accuracy of CE versus IC plus MRE for detection of active CD in  the small bowel and colon will be 
assessed.  
 
Accuracy measures (sensitivity, specificity, negative predictive value, positive predictive value) will be 
calculated for the overall bowels (small bowel and co lon) as well as for the designated bowel segments 
(proximal small bowel, terminal ileum, and colon).  
Accuracy for active CD needs to be first be meas ured for each designated bowel segment. The gold 
standard for each segment will vary:  
xMRE+CE in the proximal small bowel 
xMRE+CE+IC in the terminal ileum 
xCE+IC in the colon 
Once accuracy is defined for each segment, the da ta will be aggregated to measure accuracy for the 
overall bowels. If there is any positive finding of active CD in any of the three designated segments 
(proximal small bowel, terminal ileum, colon), it w ill be counted as positive for overall accuracy.  
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 70 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.8 Appendix G – Scores for Capsule endoscopy, 
Ileocolonoscopy, and MRE 
 
This appendix includes scores that will be used by central readers for assessment of active CD and 
mucosal disease activity using CE, IC, and MRE.  
 
xAppendix G1 – Lewis Score 
xAppendix G2 – Simple Endoscopic Score for Crohn’s Disease Index (SES-CD) Score 
xAppendix G3 – Magnetic Resonance Index of Activity (MaRIA) Score 
 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 71 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.8.1 Appendix G1 – Lewis Score 
The Lewis Score will be used to evaluate the more proximal small bowel for CE.  
 
 Number Extent Descriptors 
Villous appearance  
(worst -affected tertile) Normal – 0 
Edematous – 1 ≤10% – 8 
11-50% – 12 
>50% – 20 Single – 1  
Patchy – 14 
Diffuse – 17 
Ulcer  (worst-affected 
tertile)  None – 0 
Single – 3 
2-7 – 5 
≥ 8 – 10 ≤10% – 5 
11-50% – 10 
>50% – 15 <1/4 – 9 
1/4-1/2 – 12 
>1/2 – 18 
Stenosis (whole study) None – 0 
Single – 14 
Multiple – 20  Non- ulcerated – 2 
Ulcerated – 24 Traversed – 7 
Not traversed – 10  
 Total score will be calculated based on the most severe tertile plus the stenosis score. On central reading, 
a Lewis score of ≥ 135 will be considered active disease. 
 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 72 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.8.2 Appendix G2 – Simple Endoscop ic Score for Crohn’s Disease Index 
(SES-CD) Score 
 
The Simple Endoscopic Score for Crohn’s Disease Inde x (SES-CD) will be used to evaluate the terminal 
ileum and colon for CE and IC. On central reading, a SES-CD score of ≥ 3 will be considered active 
disease. 
 
Variable 0 1 2 3 
Size of ulcers 
(cm) None Aphthous ulcers 
(diameter 0.1-0.5) Large ulcers 
(diameter 0.5-2) Very large ulcers 
(diameter > 2) 
Ulcerated surface None < 10% 
 10-30% > 30% 
Affected surface Unaffected  
segment < 50% 50-75% > 75% 
Presence of 
narrowings  None Single, can be 
passed Multiple, can be 
passed Cannot be passed 
 
 
 
  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 73 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.8.3 Appendix G3 - Magnetic Resonanc e Index of Activi ty (MaRIA) Score 
 
The Magnetic Resonance Index of Activity (MaRIA) Sc ore will be used to evaluate the small bowel for 
MRE in accordance with Coimbra et al., Aliment Pharmacol Ther 2016; 43: 61–72 .  
 
The per segment MaRIA score is defined as: 
 
  
 
  
 WT = wall thickness of bowel in mm, meas ured at thickest point in the segment 
 RCE = relative contrast enhancement   
 Edema and ulcer are each assigned a value of 1 if there is evidence of eith er in the segment; 0 if 
 there is no evidence.  
 
 
RCE is measured at areas with the largest enhanc ement in a bowel wall segment after IV contrast 
administration:  
 
 
 
 
 
  
 
 Gd = gadolinium 
 WSI post-Gd = mean bowel wall signal intensity after Gd 
 WSI pre-Gd = mean bowel wall signal intensity before Gd 
 SD noisepost-GD  = standard deviation of MRE image in air after Gd 
 SD noisepre-GD = standard deviation of MRE image in air before Gd 
 
The MaRIA score for the small bowel and TI will be computed separately per the formula above. On 
central reading, a MaRIA score of ≥ 7 will be considered active disease. 
 
  MaRIA seg = 1.5 × WT + 0.02 × RCE + 5 × edema + 10 × ulcer  
      WSI post-Gd – WSI pre-Gd                 SDnoise pre-Gd  
                                        WSI pre-Gd                                    SDnoise post-Gd  × RCE = 100  × 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 74 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  17.9 Appendix H – Patient Sa tisfaction Questionnaire 
The questionnaire will be completed by subjects after the last baseline procedure (IC).  If the subject is 
unable to complete the questionnaire on the same da y following completion of imaging procedures due 
to sedation, the questionnaire may be completed by phone the following day. 
 
BLINK Patient Satisfaction Questionnaire 
 
Subject #: _______________ 
 
Baseline Visit: 
Which procedure would you prefer to have in the future? 
oPillCam Crohn’s capsule 
oMRE + colonoscopy 
oColonoscopy 
 
Why do you prefer this procedure? (choose all that apply) 
oless invasive 
oless discomfort 
osafer  
oless embarrassing 
ono need to be put to sleep 
ono time off of work/school 
ono need for someone to drive me 
ocutting edge technology 
osingle procedure to look at all of intestines 
ono need to be in a small space 
ocan collect tissue (biopsy) at same time 
omore familiar with it 
ostandard procedure 
omore accurate 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 75 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  oless bowel prep 
ofinds disease outside of intestines 
ono need for an IV 
ocan move around during procedure 
ono need to drink chalky solution 
oother: provide comment ___________________________________________________________ 
 
How likely are you to recommend the procedure yo u chose to others with your condition?  
onot likely 
olikely 
overy likely 
 
Name of Research Staff Obtain ing Responses from Subject: 
 _________________________________________________________________ 
 
Research Staff Signature:  _____________________________________________________ 
 
Date: ______________________________             
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 76 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  18. Version History 
Version Summary of Changes Author(s)/Title 
1.0 xN/A Mamata Thapa, PhD; 
Medical Writer 
2.0 xTransferred to new CIP template (056-F275, Version 2.0) per 
Medtronic policy. Sections were added and/or revised to meet 
global Medtronic CIP template and checklist requirements. 
xChanged “PillCam SBC” to “PillCam Crohn’s” due to renaming of 
product. 
xAdded “diagnosis based on radiological, endoscopic, or 
histological evidence” in inclusion criteria for subjects with 
known Crohn’s disease.    
xExcluded pediatric subjects. Removed procedure details and 
supporting documents (pediatric patient satisfaction and quality 
of life questionnaires) pertaining to pediatric population. 
xExcluded vulnerable subjects.  
xUpdated study status for ClinicalTrial.gov: [STUDY_ID_REMOVED] and 
[STUDY_ID_REMOVED]. 
xAdded “te rminal ileum” to bowel segmen ts that will be evaluated 
with the Lewis score.  
xRemoved “sub-investigator” designation for radiologist. 
xAdded information as required  by Medtronic checklist in 
following sections: Study Design , Product Description, Study 
Proce dures, Risks and Benefits, Statistical Design and Methods, 
Study Administration, Data Management, and Study Contact and 
Information.  
xDeleted “standard of care” si nce “IC plus  MRE” is not 
considered standard of care for monitoring CD in the small bowel and colon. Reported comparator group procedure/s at 
baseline (IC plus MRE) and 6- and 12- month follow-ups (IC 
with or without MRE).  
xModified protocol to reflect that the study will be a post-
market, 
off-label trial in the US (NSR IDE) and post-market, on-label, 
non-regulatory trial in EMEA. 
xAdded statement that the study will begin in Europe; and the 
study will begin in the US and Israel only after the product has 
been approved for use in these countries.  
xUpdated proposed indication for the US, Europe, and Israel.  
xMinor updates and minor clarific ations were made throughout 
the protocol. These minor changes did not affect the purpose or 
requirements of the study.   Mamata Thapa, PhD; 
Medical Writer  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 77 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  3.0 xUpdated version number and date 
xRemoved ADE, UADE, USADE definitions from glossary 
xUpdated Section 4 and Section 10.4 to include the exclusion 
criteria “Subject has any medica l condition that would make it 
unsafe for them to participate, per the Investigator’s discretion” 
xUpdated Section 11.2 to include collection of subject’s birth year 
in demographics 
xUpdated Section 11.4 to note an  impartial witness must also 
sign the ICF if the subject is unable to read 
xUpdated Section 11. 10 to indicate Medtro nic personnel may be 
present during capsule endoscopy procedure to provide 
technical support 
xUpdated Sections 11.8, 11.10, 11.11 to include requirement of 
transfer of imaging to Imaging Core Lab within 48 hours of 
completion of procedure 
xUpdated Section 13 to remove definitions and reporting 
timelines for ADEs, UADEs and USADEs as this will be a post-market study. Country-
specific requirements will be captured in 
Safety Plan 
xUpdated Appendix B to allow for stool PCR microorganism panel 
as an alternative to stool ova/parasite 
xUpdated Appendix C to remove administration of remaining dose 
of anti-peristaltic agent 
xUpdated Appendix E1 to clarify that subjects are required to 
remain at the endoscopy clinic un til excretion of the capsule or 
battery failure of the device (whichever comes first) 
xUpdated Appendix E3 to clarify subjects must remain in clinic for 
duration of the procedure  Jessica Carlson, 
Principal Clinical 
Research Specialist  
4.0 xMoved to v3.0 of CIP Template  
xAdded definition of stricture to Section 3 Protocol Synopsis, 
Section 8.4 Exclusion Criteria, and Section 9.5 Baseline  
xCorrected typo in Section 3 Protocol Synopsis and Section 8.4 
Exclusion Criteria #2 to change “and” to “or”  
xRemoved exclusion criteria #7 from Section 3 and Section 8.4  
xAdded Belgium to Section 3 Study Locations and throughout 
document  
xUpdated Section 4.1 to indicate  PillCam Crohn’s capsule has 
received FDA clearance in the US  
xUpdated Section 5.2.1 Primary Endpoint to “IC with or without 
MRE”  
xUpdated Section 5.2.3 Safety Endpoints to correct references in 
Section 11  
xRemoved Lewis Score as CE sc oring mechanism for terminal 
ileum throughout document  
xRemoved collection of age from Section 9.2 Subject Screening  
xUpdated Section 9.3 Prior and Concomitant Medications to 
clarify restriction on use of NSAIDs  Jessica Carlson, Clinical 
Research Specialist  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 78 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xUpdated Section 9.4 Baseline to allow responses to 
questionnaires by phone  
xUpdated Section 9 .5 Randomization and Treatment Assignments 
to clarify randomization procedures.  
xRemoved requi rement for withdrawal time of IC endoscope to 
be at least 6 minutes from Section 9.12  
xAdded definition of subtle lesions to Section 9.13.1  
xRemoved reference to USADEs from Section 11 as this does not 
apply to a post-market trial  
xReference to “Medical Advisor Charter” removed from Section 
12.1  
xUpdated Section 13.5 to indicate subjects Subject ingesting 
<2.5L of PEG bowel preparation prior to CE or IC procedure will 
be excluded from analysis 
xAdded clinicaltrials.gov study identifier to Section 14.1 
Statement of Compliance  
xUpdated Appendix C “MRE Procedure Instructions” to clarify 
choice of Breeza or Volumen as oral non-absorbable bowel preparation solution
 
xAdded Appendix C1 “MRE Subject Instructions”  
xUpdated Appendix E3 “CE Procedure Instructions” to align with 
Appendix E2 “CE Subject Instructions” and to allow subjects to 
leave the clinic if procedure is not complete at 10 hours  
xAppendix E2 “CE Subject Instructions” updated to provide more 
clear instruction  
xAppendix F1 “IC Bowel Preparation” to indicate clear liquid diet 
only on day of procedure  
xUpdated Appendix H3 to clarify calculation of MaRIA score.  
xUpdated Appendices I and J to reflect that questionnaires may 
be completed via phone call with subject  
xAppendix I “Patient Satisfaction Questionnaire” updated to 
include information regarding re search staff collecting subject 
responses.  
xAppendix J attachments “EQ-5D- 3L” and “Inflammatory Bowel 
Disease Questionnaire” updated to include information regarding 
research staff collecting subject responses. 
5.0 xUpdated document version numbe r to version 5 in Header, 
Footer, Title page and Investigator Statement 
xAdded term NPO and definition  to Section 2 – Glossary 
xRemoved Germany as a participating country throughout 
document 
xUpdated Primary Objective, Secondary Objectives #1 and #2, 
Primary Endpoint, and Secondary Endpoints #1 and #2 to 
indicate “CE as compared to IC pl us MRE” instead of “IC with or 
without MRE” as these outcomes  are determined by baseline 
data when all subjects will und ergo all imaging procedures. Jessica Carlson, 
Principal Clinical 
Research Specialist  
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 79 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xSection 5.2.3 – Safety Endpoints: Removed “All AEs will be 
captured, regardless of severity or  relationship to the procedure” 
as only the adverse events defined in Section 11.1 are being 
collected. 
xUpdated Section 7.9 – Product Receipt and Tracking to clarify 
study equipment and device will be  sent to site upon execution 
of Clinical Trial Agreement to allow adequate time for shipment 
and installation but site is not allowed to use product or begin 
enrollment until the Sponsor provides notification of Site 
Activation.  
xUpdated Section 9.1 – Schedule of Events and Appendix B – 
Study Schedule for Clinical Laboratory and Pregnancy Tests to 
clarify Screening Procedures should occur no more than 30 days 
prior to baseline MRE, not 30 days prior to baseline IC as 
previously sta ted.  Removed requirement for Baseline pregnancy 
test as deemed not clinically ne cessary given timing of screening 
pregnancy test.   
xUpdated Section 9.1, Footnote #3 to indicate all required labs 
should take place no more than 14 days prior to the first 
imaging procedure at any given visit timepoint to remain within 
required visit windows. 
xUpdated Section 9.5 – Baseline and 9.12 - Ileocolonoscopy to 
indicate physician may instru ct subject to be NPO after 
completion of baseline CE Procedure to prepare for IC procedure 
and associated sedation. 
xUpdated Section 11 – Adverse Events and Device Deficiencies 
for clarity.  
xUpdated Section 11.1 – Definitions/Classifications to clarify all 
AEs related to subject’s Crohn’s di sease, all device deficiencies 
and all SAEs should be reported 
xUpdated Section 11.1.2 – Serious Adverse Event (SAE) to 
remove “that is not related to the device comparator or study 
procedure” from the definition 
xChanged Emergency Safety contact to Safety Representative 
email in Section 11.3 – Reporting of Adverse Events 
xUpdated Section 13 “Statistical Design and Methods” to correct 
analysis population to align with primary endpoint and provide 
additional clarifications. 
xSection 15.2.4 – Data Queries - Added clarification that queries 
related to imagin g will be issued by ICON through the SQUARE 
system. 
xAppendix C – MRE Procedure Instructions updated to clarify 
procedural requirements per Lead Radiologist 
xAppendix C1 – MRE Subject Instructions updated to correct a 
page numbering error 
xAppendix E1 – CE Bowel Prep Instructions and Appendix E2 – 
CE Subject Instructions updated to be easier to understand and 
follow for research staff and study subjects.  Additionally, 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 80 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  250mg oral Erythromycin has been added as an acceptable 
substitute for 10mg Metoclopramide at Alert 0. 
xAppendix E3- CE Procedure Instructions updated to be easier to 
understand and follow.   
xAppendix F1 – Ileocolonoscopy Bowel Preparation and Appendix 
F2 – Ileocolonoscopy Subject Instructions updated to be easier 
to understand and follow for rese arch staff and study subjects. 
Removed Bowel Prep requirements for 2 days prior to the 
procedure, including removal of requirement for subject to take 
4 Senna tablets.  Provided clarification, that as required, 
subjects should be instructed to be NPO prior to any sedation 
for the ileocolonoscopy per standard care. 
6.0 xUpdated entire document to remove 3, 6, 9, and 12 month 
follow-up visits (and associated procedures) throughout.  
xRemoved Appendices J1 EQ-5D-3L and J2 Short IBD 
Questionnaire 
xCombined Appendices E1 CE Bowel Preparation Instructions and 
F1 Ileocolonoscopy Bowel Preparation Instructions 
xCombined Appendices E2 C E Subject Instruction Form and F2 IC 
subject Instruction Form.   
xAdded lines for Subject and Study Coordinator signature and 
date to Appendix C1 MRE Subjec t Instructions and Appendix E2 
CE and IC Subject Instructions for verification of source 
documents 
xUpdated document to version 6 in Header, Footer, Title page 
and Investigator Statement 
xAdded “or other clinical evidence” to Study Design section of 
Synopsis 
xRemoved other European countries throughout, leaving Austria  
xUpdated Inclusion Criteria #4 to include subjects with known CD 
and active disease, based on  clinical judgment based on 
symptoms, laboratory data or other clinical information. 
xRemoved “any current condition believed to have an increased 
risk of capsule re tention such as” from Exclusion Criteria #7 for 
clarity and to reduce redundancy. 
xAdded Exclusion Criteria #17, “Subject with ileostomy or 
colostomy, history of total or subtotal colectomy (including those 
with ileosigmoidostomy, and ileorectostomy” 
xClarified AE reporting requirements in Sections 5.2.3, 11.1, 11.2, 
13.4 to specify that reporting of AEs should start beginning with 
first baseline imaging procedure (MRE). 
xUpdated language in Section 6 Study Design in alignment with 
Inclusion Criteria #4 to all ow enrollment of subjects with current 
active disease based on symptoms, laboratory data, or other clinical information 
x
Increased maximum number of enro lled subjects from a single 
site to 70 (20%) in Section 6.1 Duration Jessica Carlson, Clinical Research Manager
 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 81 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xUpdated Section 7.10 Product Storage to indicate Temperature 
Logs are not required for BLINK as storage is expected at 
ambient temperature 
xUpdated footnotes in Table 1 Schedule of Events to provide 
additional clarity 
xAdded clarification to Section 9. 2 Screening Visit that Medical 
History sh ould include any history within the last 2 years related 
to the study inclusion/exclusion criteria; Previous GI Procedures 
should be captured for the last 5 years; and Surgical History should include only GI-related surgeries 
xClarified Section 9.5 Baseline 
to include: completion of MRE to 
completion of IC should be no more than 4 weeks, all baseline 
labs must be completed no more than 14 days prior to baseline 
MRE, and instruction regarding de termination of patency prior to 
capsule endoscopy 
xRemoved “pregnancy test” from Section 9.5 Baseline in 
alignment with Baseline Laboratory requirements 
xClarified Section 9.10 PillCam Pa tency Study to designate when 
subjects should be exited from trial due to stricture and when 
patency procedure should be completed 
xAdded additional detail to Section 9.13 Central Reader 
Image/Video Reading to indicate procedures for assessing 
disease activity in cases where an imaging modality is not 
available for evaluation 
xAdded detail of specific PillCam Crohn’s procedure- related AEs 
that must be reported 
xClarification added to Section 13.5 Analysis Populations for 
handing of subjects with missing imaging 
xRemoved all interim analyses in Section 13.6 Interim Analyses  
due to enrollment ending in April 2019 
xAdded footnote to Appendix B Study Schedule for Clinical 
Laboratory and Pregnancy Tests to clarify that standard of care 
C. Difficile and Stool O&P lab results may be used for trial 
purposes provided the date of results is no more than 90 days 
prior informed consent date 
xAppendix C MRE Procedure Instructions updated to include 
allowance of split does of anti -peristaltic agent and increased 
imaging thickness for larger patients 
xCorrected typo in Appendix C1 MRE Subject Instructions 
xAdded additional clarification to Appendix D PillCam Patency 
Procedure to make instructions easier to follow 
xAdded additional clarification to Appendix E1 CE Bowel 
Preparation Instructions to make them easier to follow 
xAdded additional clarification to Appendix E2 CE Subject 
Instructions Form to make it easier to follow 
xAdded additional clarification to Appendix F1 Ileocolonoscopy 
Bowel Preparation Instructions to make them easier to follow 
BLINK Clinical Investigation Plan  
  
 Version 6.0 Page 82 of 82  
 
Medtronic Confidential  
This document is electron ically controlled   056-F275, v3.0 C linical Investigation Plan Template 
  
  xAdded active disease scoring thre sholds to Appendix G1 Lewis 
Score, Appendix G2 SES-CD Score, and Appendix G3 MaRIA 
Score for transparency 
 